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ABSTRACT
Yang, Yifan Ph.D., Purdue University, May 2018. From Pieces To Paths: Combining
Disparate Information in Computational Analysis of RNA-Seq. Major Professor:
Michael Gribskov.
As high-throughput sequencing technology has advanced in recent decades, largescale genomic data with high-resolution have been generated for solving various
problems in many felds. One of the state-of-the-art sequencing techniques is RNA
sequencing, which has been widely used to study the transcriptomes of biological
systems through millions of reads. The ultimate goal of RNA sequencing bioinformatics algorithms is to maximally utilize the information stored in a large amount
of pieced-together reads to unveil the whole landscape of biological function at the
transcriptome level.
Many bioinformatics methods and pipelines have been developed for better achieving this goal. However, one central question of RNA sequencing is the prediction
uncertainty due to the short read length and the low sampling rate of underexpressed
transcripts. Both conditions raise ambiguities in read mapping, transcript assembly,
transcript quantifcation, and even the downstream analysis.
This dissertation focuses on approaches to reducing the above uncertainty by
incorporating additional information, of disparate kinds, into bioinformatics models
and modeling assessments. I addressed three critical issues in RNA sequencing data
analysis. (1) we evaluated the performance of current de novo assembly methods and
their evaluation methods using the transcript information from a third generation
sequencing platform, which provides a longer sequence length but with a higher error
rate than next-generation sequencing; (2) we built a Bayesian graphical model for
improving transcript quantifcation and di˙erentially expressed isoform identifcation

xiv
by utilizing the shared information from biological replicates; (3) we built a joint
pathway and gene selection model by incorporating pathway structures from an expert
database. We conclude that the incorporation of appropriate information from extra
resources enables a more reliable assessment and a higher prediction performance in
RNA sequencing data analysis.

1

1. INTRODUCTION
1.1

A brief history of sequencing technology
Each small step of a human being is built on the steps of pioneers in history. To

learn about the history of sequencing technology or even of molecular biology will
help us understand where we are in this long river of time, and why we carry out
studies depicted in this dissertation.
For thousands of years, people persistently pursued the answer of one central
question about life – what is life and how are the traits of lives inheritated on and
on? Until 1953, when James D. Watson and Francis Crick frst deduced the structure of DNA molecules (Watson and Crick, 1953), and when Francis Crick proposed
the Central Dogma of biology (Crick, 1958), which frst summarized how sequence
information was transferred from DNA to RNA and from RNA to protein; the era
of molecular biology had began. Researchers started to wonder whether these magic
DNA and RNA molecules could be sequenced, and the sequences stored as a “Bible
of Life” so that our descendants would be able to decipher this huge and treasured
book, and answer the central question about life.
DNA sequencing is actually a fairly new feld in our history (Metzker, 2008; Kulski, 2016). From 1977, about 25 years after the discovery of the DNA double helix
structure, when Sanger and Maxam/Gilbert frst invented the technology of DNA sequencing, until today, when sequencing techology has been widely industrialized and
applied in many felds, it has only been about 40 years. I would like to divide these
40 years into three big stages, marked by di˙erent historical events as milestones. Of
course, with the development of sequencing technology, the need for both computer
hardware and software (e.g. databases and bioinformatics algorithms), has greatly
increased.

2
The frst stage of sequencing technology is from 1977 to 1990. During this period,
people, for the frst time, invented DNA sequencing techology with the ability to sequence short genomes up to thousands of base pairs; in the same period, databases
for storing sequences and corresponding algorithms for searching sequences were initialized. The story should be backdated to 1965, when the frst nucleic acid molecule
– yeast alanine-tRNA – was sequenced (Holley et al., 1965). Believe it or not, it took
researchers about 7 years to prepare a 1 gram tRNA sample from yeast, and the sequencing was purely based on chromatographic and spectrophotometric procedures,
which was extremely time-consuming and labrious – only several bases could be sequenced per year ! In 1977, two sequencing methods – Maxam and Gilbert’s chemical
degradation method (Maxam and Gilbert, 1977) and Sanger’s chain-termination sequencing method (Sanger et al., 1977) – were published, and competed with each
other for years. Eventually, Sanger’s method prevailed over the Maxam/Gilbert’s
method due to its greater simplicity and robustness, and dominated the sequencing
feld for the next 20 years. In 1986, Sanger’s sequencing method was frst incorporated into an automated instrument, which was marketed by Applied Biosystems
Instruments (ABI), and sequencing speed reached 1,000 base pairs per day. Another
epoch-making technology, which was invented by Mullis in 1983 (Saiki et al., 1985),
is the polymerase chain reaction (PCR) technology, facilitating the development of
sequencing technology by amplifying DNA molecules to a high concentration. In
the area of databases and bioinformatics algorithms, GenBank was founded in 1982,
and the BLAST algorithm (Altschul et al., 1990), the most widely used approach to
identifying similar sequences in sequence databases, was developed in 1990.
The second stage is from 1990 to 2005. During this period, steady advances
were made in sequencing technology, and the number of sequences submitted to the
database explosively increased; Many sequencing centers around the world were established; meanwhile, Sanger’s chain-termination sequencing method was still dominant
in the feld, although signifcant advances were made in increasing throughput by
moving from gel to capillary electrophoretic methods. In these 15 years, researchers
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started sequencing genomes of many species, ranging from viruses, protists, fungi,
and plants, to animals (Primorose and Twyman, 2006), e.g. Haemophilus infuenzae, the frst genome of a bacterium, was sequenced in 1995; the genome of Saccharomyces cerevisiae, the frst eukaryotic genome to be sequenced, was completed in
1996; Caenorhabditis elegans, the frst genome of a multicellular organism, completed
in 1998; Arabidopsis thaliana, the frst plant genome, completed in 2000; Homo sapiens, the frst mammalian genome, completed in 2001; Oryza sativa (rice), the frst
crop genome, completed in 2002; Mus musculus (mouse), a widely used mammalian
model organism, completed in 2002/3; and Pan troglodytes (chimpanzee), the closest
relative to humans, completed in 2005. One event that I cannot overemphasize is
the Human Genome Project (HGP), which started in 1990 and ended in 2003. This
13-year project, for the frst time, sequenced the genome of humankind, and mapped
the human genome to many other genomes (Chial, 2008). As an international collaboration of eighteen countries, this project not only raised sequencing technology to a
global scope, but also built a foundation for much of the human health research of
today. Due to the global impact of the HGP, many centers and institutes for genome
sequencing and genome study were established at that time, such as The Institute for
Genome Research (TIGR), now known as the J. Craig Venter Institute, in the USA,
the Sanger Center in the United Kingdom, and RIKEN in Japan, etc. By the end
of 1998, sequencing speed had reached 500,000 to 1 million bases per day using the
ABI Prism 3700 multiple capillary sequencer (Metzker, 2008). For data storage at
that time, the genomic sequences were kept in relational database management systems. Researchers could access sequences from websites (and ftp). The data transfer
was no longer accomplished by mailing magnetic tapes, but done using the internet.
For bioinformatics algorithms, because most of the genomes were sequenced by the
shotgun strategy, genome assembly algorithms were developed and widely applied
(Kulski, 2016; W. Myers Jr, 2016). Meanwhile, the frst technologies for measuring
gene expression (i.e., RNA abundance), the high density oligonucleotide arrays (mi-
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croarrays), appeared in around 1996. Microarray technology actually dominated the
feld of gene expression analysis for about a decade (Southern, 2001).
The third stage is from 2005 to 2017. During this period, a number of new sequencing methods were widely commercialized and replaced Sanger’s method; RNA sequencing (RNA-seq) has become the primary approach for studying transcriptomes of
biological organisms. The new sequencing methods introduced beginning in 2005 are
the so-called “second generation sequencing” or “next generation sequencing” (NGS).
The most commonly used platforms for second generation sequencing were Roche 454
pyrosequencing (discontinued in 2013), Illumina, SOLiD, DNA nanoball sequencing,
and Ion torrent (Kulski, 2016; Heather and Chain, 2016; Liu et al., 2014). Instead
of cloning individual DNA fragments via foreign host cells as in Sanger’s method,
the new methods have much easier and quicker library preparation procedures using
adapters, barcodes, primers, new PCR methods, and novel sequencing mechanisms;
high throughput sequencing can be achieved by amplifying DNA clusters on a solid
substrate with readout by charge-coupled device (CCD) cameras, producing the sequences of hundreds of thousands (Roche 454) to hundreds of millions of fragments
simultaneously. Though each platform has its own pros and cons, the cost of second
generation sequencing, (e.g. Illumina HiSeq), is much lower – about 300 thousand
times cheaper than Sanger’s method – per million bases (Liu et al., 2014; Muir et al.,
2016). The reduced cost of sequencing immediately led to a second wave of increasing amounts of data. To adapt to the drastically increased data scale, remote data
analysis by cloud computing has become available, and is now starting to be widely
used (Dai et al., 2012; O’Driscoll et al., 2013). Databases have also become more
diverse and specialized than before (Zou et al., 2015). Moreover, new bioinformatics
algorithms, such as read alignment algorithms, read assembly algorithms, data compression algorithms, and data mining algorithms for extracting useful information
from the omics data have been developed (Berger et al., 2013).
Very recently, other leading-edge sequencing technologies, such as PacBio, Helicos, Nanopore, and electron microscopy sequencing, have emerged. These sequencing
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methods are called “third generation sequencing” to di˙erentiate them from the “second generation sequencing” (Liu et al., 2014; Heather and Chain, 2016). These new
methods try to sequence DNA molecules at a single molecule level, without complex
fragmentation, ligation, or amplifcation steps. In theory, such approaches should be
less technically biased and able to produce longer read lengths than second generation
sequencing. However, the problems with these approaches, such as high sequencing
error rate and low read coverage, etc., are still present, and need to be solved in the
future.
Looking back, over a short period of 40 years, sequencing technology has gone
through from zero to one, and one to more. The overall trend is that the sequencing has become faster, cheaper, and more precise at determining and measuring the
expression of real transcriptomes of organisms. As a result, the amount and scale of
sequencing data will continue to increase; and bioinformatics algorithms for analyzing
big genomic data are urgently needed.
My Ph.D. study focuses on developing and evaluating bioinformatics algorithms
for RNA-seq data analysis. In the next section, I will briefy introduce RNA-seq and
its applications.

1.2

Signifcance of RNA Sequencing and its applications
The NGS technology has a variety of applications depending on the goal of the re-

search. Some common applications include whole genome sequencing (WGS), whole
exome sequencing (WES), targeted sequencing of specifc genes, chromatin immunoprecipitation sequencing (ChIP-seq), and RNA-seq. Among the above sequencing
methods, RNA-seq is a state-of-the-art technique that takes advantage of the highthroughput of NGS for studying dynamic and tissue-specifc transcriptomes. Another
method, which was widely used in the 1990s to study transcriptomics, is the microarray technique, based on oligonucleotide hybridization. However, since around 2005,
as the cost of per base of RNA-seq and the sequencing quality have continuously
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improved, RNA-seq has taken over from microarray approaches, becoming the frst
choice for quantitatively assessing gene expressions in biological systems. Extensive
reviews have been published on how RNA-seq has revolutionized our view of biological
processes and pushed forward the biomedical feld (Han et al., 2015). Most recently,
due to the decreasing cost of RNA-seq and its powerful ability for providing fast and
accurate quantifcation of RNA levels, the RNA-seq technique has been standardized
and translated to the medicine and healthcare felds in the real world.

1.2.1

RNA-seq in scientifc explorations

RNA-seq has completely changed our view of the landscape of the human transcriptome by discovering new transcripts, identifying novel mutations, quantifying
transcripts at the isoform level, and enabling comprehensive di˙erential expression
and functional analysis. About 10 years ago, people thought that only 3% of human genome was transcribed as messenger RNA (mRNA), based on mapping of the
expressed sequence tags (ESTs) back to the genome. Until very recently, when substantial RNA-seq data frmly established the reality of pervasive transcription – more
than 85% of the human genome is transcribed, although only 3% is eventually translated to proteins (Hangauer et al., 2013). These non-coding transcripts have been
identifed as belonging to previously unknown classes of RNAs, such as long noncoding RNA (lncRNA), microRNA (miRNA), small interfering RNA (siRNA), and
enhancer RNA (eRNA) (Iyer et al., 2015; Guo et al., 2015; Kim et al., 2010). These
new discoveries have dramatically changed our understanding of the human genome
and enriched our knowledge of gene regulation.
In addition to the “junk” regions of human genome, RNA-seq has also led to
new discoveries in coding sequence regions. Using RNA-seq, many genes have been
found to have alternative isoforms (an average of 3.4 alternative isoforms per gene
according to GENCODE human annotation version 271 ) (Li et al., 2014), although
1

https://www.gencodegenes.org/stats/archive.html

7
most genes have only one dominant isoform in most conditions (Trapnell et al., 2010;
Gonzàlez-Porta et al., 2013). Multiple isoforms can result from either the switch
of transcriptional start sites (TSS) on the genome, or from the complex alternative
splicing process during the transcript maturation. Many studies have found that
isoforms of the same gene can have the opposite functions by regulating the same
complex or pathway (Li et al., 2014; Tone et al., 2001). Aberrant splicing events,
and fusion genes with abnormal exon-intron structures, or copy number variations,
also have been found to be related to diseases, especially in cancers (Fackenthal and
Godley, 2008; Eswaran et al., 2013). These discoveries have led to new hypotheses
for human transcriptome and transcriptional regulation.
The single nucleotide resolution of RNA-seq enables highly sensitive and accurate
quantifcation of transcripts. By comparing the transcriptomes of di˙erent tissues,
or at di˙erent times, many interesting mechanisms have been unraveled at the transcriptome level.

1.2.2

RNA-seq in translational medicine

As the a˙ordability and reliability of RNA-seq have improved, many research
groups and companies have started to translate RNA-seq technology into healthcare.
One promising direction is personalized medicine, in which a therapeutic plan is made
based on the genomic information of each patient (Rabbani et al., 2016). Due to genomic variations in the human population, the conventional strategy of “same disease
– same drug” has been gradually replaced by a concept of personalized medicine, or a
“same disease – di˙erent drugs” strategy. One successful case, which has already entered the clinical trial stage, is the design of personalized cancer vaccines for treating
melanoma2 (Ott et al., 2017; Sahin et al., 2017). RNA-Seq and exome sequencing were
used to identify tumor-specifc mutations in each patient, and the mutant proteins
that are most likely to trigger immune system responses to invading cancer cells, were
2
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selected to generate a mixture of vaccines. In two independent studies (Ott et al.,
2017; Sahin et al., 2017), four out of six and eight out of thirteen patients were tumor
free one year after receiving the vaccine treatment.
Another direction that RNA-seq has been translated to is precision medicine, in
which clinical diagnosis, prognosis and medical screening are made by precisely sequencing and measuring the biomarkers of individual patients (Byron et al., 2016).
Based on the genomic information, healthcare providers can make better plans for disease treatment and lifestyle adjustment. For example, FoundationOne Heme, which
has been approved by the US Food and Drug Administration (FDA), employs RNAseq technology for detecting oncogenic fusions in hematologic malignancies and sarcomas. FoundationOne Heme provides useful information to physicians for diagnosing
hematological cancers. An emerging area is the measurement of the levels of extracellular RNA (exRNA) by RNA-seq for diagnosing a disease or monitoring the process
of a disease (Byron et al., 2016). It is appealing because exRNAs exist in biofuids, which can be non-invasively acquired from patients. The US National Center
for Advancing Translational Sciences (NCATS) initiated an exRNA communication
consortium in 2015 for developing diagnostic tools.
Aside from the above translational studies and applications using RNA-seq, many
companies have been launched that seek to translate the sequencing technology into
healthcare3 . Some companies focus on providing direct healthcare services, including
cancer gene profling, pharmacogenomic toxicity analysis, and therapy counseling.
For example, Veritas genetics provides whole genome sequencing, and links the disease risk analysis using smartphone apps; IBM Watson for genomics, announced in
January 2017 that it will be integrated into Illumina’s TruSight Tumor 170 tool for
speeding up drug recommendations for cancer patients; Rosetta genomics employs
a NGS-platform for providing genome-wide oncogenomic tumor profling and pharmacogenomic toxicity analysis specifcally for lung cancer patients. Some companies
emphasize integrating machine learning methods into data analysis. For example,
3
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Verge genomics, which uses machine learning and genomics data for providing new
treatment options specifcally for neurodegenerative diseases; Verily Life Science, a
healthcare company subsidiary of Google, aims to use mature google learning algorithms for solving healthcare issues.

1.3

General workfow of RNA-seq data analysis and related bioinformatics algorithms
Currently, the most typical RNA-seq platform provides sequencing of paired-end

reads with the length of about 100 – 250 base pair (bp), and the numbers of reads
ranging from 5 to 60 million per sample, depending on the goal of the sequencing.
However, because of the broad applications of RNA-seq, as I introduced in Section
1.2, there is not a universal workfow for all RNA-seq data analyses. Considering the
majority of studies, which aim to systematically interpret biological functions using
RNA-seq data, I outline a general workfow of RNA-seq data analysis in Figure 1.1,
which also highlights the focus of this dissertation.
Figure 1.1 (A) shows the major steps of RNA-seq data analysis including the
construction of a transcriptome (assembled transcripts) from RNA-seq reads, the
quantifcation of transcripts, and the interpretation of biological functions (e.g. using
networks) based on the experimental design. Following such a workfow, the massive
information stored as millions of short-read sequences will be transferred into organized biological networks, which can be visualized and analyzed by domain experts.
After sequencing, RNA-seq raw reads will frst be pre-processed by removing lowquality reads (e.g. the reads with a total base quality in a window lower than a
threshold) and artifacts (e.g. adaptors, contaminant DNAs and PCR duplicates)
(Martin and Wang, 2011). Then the preprocessed reads will be used for constructing
transcripts depending on the availability of a reference genome/transcriptome. Figure
1.1 (B) shows a detailed workfow of RNA-seq data analysis. If the reference genome
or transcriptome are highly reliable, we can directly use the annotations for quanti-
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Fig. 1.1.: A general workfow of RNA-seq data analysis. (A) is a cartoon fowchart
that shows how the information fows from RNA-seq short reads to transcripts, and
then to gene expression and functional networks. (B) shows a detailed workfow
based on the availability of reference genome and transcriptome (red crosses mark
information that is unavailable). My three works (chapter 2, 3, and 4) focus on the
parts with green color.

fying transcripts; if only the reference genome is available, and the transcriptome is
unknown or unreliable, we can rely on a reference-based assembly method to obtain
assemblies as transcripts; if neither the reference genome nor the transcriptome is
available, de novo assembly becomes the only choice for identifying transcripts from
RNA-seq reads. Then, based on the known or assembled transcripts (reference-based
assemblies or de novo assemblies), we can quantify the transcripts by mapping preprocessed RNA-seq short reads back to the transcripts/assemblies and estimating the
count of reads that are potentially coming from each transcript/assembly. Based on
the expression levels of transcripts, functional analysis is performed for illustrating
important genes/gene clusters/pathways associated with a phenotype or a disease.
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Fig. 1.2.: Overview of the RNA-seq de novo transcriptome assembly strategy. (A)
shows all substrings of length k (kmers) are generated from every single read. (B)
shows the generation of a De Bruijn graph using kmers. Each node represents a
unique kmer and each arrow represents the overlap of k-1 bases between two kmers.
(C) shows that the non-branching chains in a De Bruijn graph can be collapsed into a
single node. (D) shows all the possible transcripts assembled by traversing the paths
in the De Bruijn graph.
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Because Chapter 2 focuses on RNA-seq de novo assembly, I will briefy introduce
some basic concepts and nomenclatures used in RNA-seq de novo assembly. Figure
1.2 shows a typical strategy of RNA-seq de novo assembly with four steps. In the frst
step (A), all the RNA-seq reads will be chopped into substrings of length k (kmers)
by shifting one base at each time; in the second step (B), De Bruijn graphs will be
constructed using all or the most frequent kmers; Each node represents a unique kmer
and each arrow represents the overlap of k-1 bases between two kmers; in the third
step (C), De Bruijn graphs will be simplifed by collapsing non-branching chains of
nodes and trimming o˙ the branches with low weights (e.g. less frequent and lowquality kmers); in the last step (D), transcripts will be generated by traversing paths
in De Bruijn graphs. Some algorithms call these resulting transcripts as contigs, and
connect contigs which are supported by read evidence for generating transcripts.
Transcriptome assembly is potentially more complicated than genome assembly.
In genome assembly, the sequencing depth is presumably the same at each base if not
considering the technical bias and sample decay, because there are no copy variations
of DNA. In contrast, transcriptome assembly methods have to consider the variations
of expression levels of transcripts in a sample, so we cannot assume the sequencing
depths are even at all bases; the PCR amplifcation step may even enlarge these
variations; also, low-expressed transcripts often have too few reads, which are hard
to be assembled. Therefore, transcriptome assembly and its evaluation methods are
still challenging questions in RNA-seq data analysis.
Lastly, for each part of the fowchart in Figure 1.1, I summarize the properties of
state-of-the-art bioinformatics algorithms and the methods related to this dissertation
in Table 1.1, including read preprocessing methods, read alignment methods, de novo
assembly methods, de novo assembly evaluation methods, transcript quantifcation
methods, di˙erential analysis methods, and functional analysis methods.
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Table 1.1.: Summary of commonly used bioinformatics
programs and the methods related to this dissertation
for RNA-seq data analysis.
Steps
Read pre-

Methods
FastQC

processing

Read

Properties and comments
• A sequencing base quality evaluator
• Provides visualization of read statistics and

Trimmomatic

qualities
• Removes adapters

BWA

• Trims low qualilty bases for RNA-seq reads
• Maps low-divergent sequences against a large

alignment

reference genome based on Burrows-Wheeler

(mapping)

transform
• BWA-backtrack is designed for Illumina sequence reads up to 100bp
• BWA-SW and BWA-MEM mapped reads from
Bowtie

70bp to 1Mbp
• A fast RNA-seq short read (< 50 bp) aligner
• Aligns reads to a reference genome indexed by
Burrows-Wheeler transform

Bowtie2

• Only non-gapped and end-to-end alignment
• A fast read aligner supporting longer read
length (< 1, 000 bp)

Tophat

• Both gapped and local alignment
• An RNA-seq read aligner built on Bowtie
• Detects splice junctions
Continued on next page

14
Table 1.1 – continued from previous page
Steps

Methods
STAR

Properties and comments
• An RNA-seq read aligner using maximum mappable prefx search
• Handles both RNA-seq paired-end short reads
and long single reads generated by the third
generation sequencing technologies
• Detects both splice junctions and chimeric tran-

GMAP

scripts
• Initially designed for cDNA alignment to reference genome (splice-aware)
• Applicable to single RNA-seq short reads (< 75
bp) with specifc parameter settings as suggested in manual4
• Applicable to PacBio long reads with optimized

De

novo

assembly

SOAPdenovoTrans
Trans-ABySS

parameters as recommended in tutorial5
• An RNA-seq short read assembler based on
SOAPdenovo
• An RNA-seq short read assembler based on
ABySS
• TransABySS-merge can merge multiple de novo
assemblies with di˙erent kmers
• No gene-isoform relation preserved
Continued on next page
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Table 1.1 – continued from previous page
Steps

Methods
IDBA-Tran

Properties and comments
• Employs a progressive probabilistic approach to
iteratively remove erroneous kmers in de Bruijn
graph construction, instead of using a global
threshold
• Designed for better assembly of low-expression
transcripts

Trinity

• No gene-isoform relationship preserved
• Both genome-guided and de novo transcriptome assembly
• Three steps: searching paths in kmer graphs to
generate linear contigs; clustering the contigs
and constructing individual De Bruijn graph for
each cluster; tracing the paths and reporting
transcripts

Oases

• Kmer size only varies from 25 bp to 32 bp
• An RNA-seq short read assembler based on the
Velvet assembler

De

novo

rnaQUAST

• Merges assemblies made with multiple kmers
• A metric-based RNA-seq assembly evaluator

assembly

• Only provides reference-based evaluation

evaluation

• Allows to de novo assemble transcripts using
several thrid-party tools, such as BUSCO and
GeneMarkS-T
Continued on next page
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Table 1.1 – continued from previous page
Steps

Methods

Properties and comments

DETONATE

• A model-based RNA-seq assembly evaluator
• Module REF-EVAL is used for reference-based
evaluation
• Module RSEM-EVAL is used for de novo as-

TransRate

sembly evaluation without reference
• A model-based de novo asssembly evaluator
• Provides contig scores for all contigs and an assembly score for the whole set of assemblies
• Removes low quality assemblies by optimizing

Transcript

Cu˜inks

quantifca-

an empirical function
• Provides reference based RNA-seq assembly for
detecting novel transcripts

tion

• Estimates expression levels of genes/transcripts
based on a given reference or a self-assemblied
transcriptome
• Cu˙di˙ used for di˙erential expression analysis
of genes/transcripts
MISO

• No assembly function
• Exon-centric model estimates the expression
levels of exons
• Isoform-centric model estimates the expression
levels of spliced isoforms
• Bayes factor (BF) evaluates the signifcance of
di˙erentially expressed (DE) isoforms
Continued on next page
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Table 1.1 – continued from previous page
Steps

Methods
RSEM

Properties and comments
• Estimates expressions of genes/transcripts with
or without a reference genome
• Employs

EBSeq

to

evaluate

DE

genes/transcripts
• Provides visualization tools
• An RNA-seq read simulator if given the expresBitSeq

sion levels of trancripts
• A 2-step model for estimating gene/transcript
expression levels frst in each replicate, and then
the mean expressions in each condition
• The probability of log-ratio of expression in condition 2 over expression in condition 1 is used

DEIsoM

to evaluate transcript DE levels
• A one step integrated model for estimating
gene/transcript expression levels in a whole
condition which is comprised of multiple biological replicates
• No loss of any sources of variations from either
ambiguous mapping or biological replication
• Kullback-Leibler (KL) divergence is used to
evaluate transcript DE levels between two con-

Di˙erential
analysis

DESeq2

ditions
• Identifes DE genes based on RNA-seq count
data
• Models the count data as a negative binonial
distribution and a shrinkage estimator for distribution variance
Continued on next page

18
Table 1.1 – continued from previous page
Steps

Methods
EdgeR

Properties and comments
• Examines di˙erential expression of replicated
count data using an overdispersed Poisson
model accounting for both biological and technical variability
• Empirical Bayes methods are used to moderate
the degree of overdispersion across transcripts
• Applicable to other data (e.g. proteome peptide
count data)

EBSeq

• Identifes not only DE genes but also DE
isoforms by considering the uncertainty from
ambiguous read mapping using an empirical
Bayesian method

Pathway

GSEA

analysis

• Evaluates DE between two or more conditions
• Determines whether an a pre-defned set of
genes shows statistically signifcant, concordant
di˙erences between two biological states
• The pre-defned set of genes can be from the
Molecular Signature Database (MSigDb) or

SeqGSEA

from users’ gene set fles.
• Improved from GSEA to adapt to RNA-seq
data with fewer biological replicates
• Incorporates the absolute gene statistic in onetailed GSEA to lower the false positive rate in
the GSEA gene permutation method
• Uses negative binomial distribution to model
read count data
Continued on next page
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Table 1.1 – continued from previous page
Steps

Methods
NaNOS

Properties and comments
• Jointly selects both genes and pathways associated with a phenotype
• Incorporates pathway structures encoded in the
database
• Eÿcient inference algorithm

In this dissertation, I will focus on three parts of the fowchart (Figure 1.1), shaded
in green, including the assessment of de novo assembly methods, the modeling of
transcript quantifcation and DE isoform identifcation, and the association of genes
and pathways with phenotypes using high throughput genomic data. I will discuss
the challenges and potential solutions in the next section.

1.4

Three critial issues in RNA-Seq analysis (Outline of the dissertation)
Despite many successful applications of RNA-seq in both scientifc explorations

and translational medicine, as I introduced in Section 1.2, multiple challenges in RNAseq data analysis are still present. The central goal of RNA-seq data analysis is to
maximally use the information stored in millions of RNA-seq reads for reconstructing
the transcriptome and understanding the biological functions associated with the
specifc spatiotemporal phenotype.
Many bioinformatics algorithms and pipelines have been developed to accomplish this goal. However, one critical challenge is the prediction uncertainty due to
the short read length and the low sampling rate of weakly expressed transcripts.
Both conditions lead to ambiguities in read mapping, transcript assembly, transcript
quantifcation, and even downstream analyses, when dealing with RNA-seq data. A
central idea behind reducing the uncertainty is to incorporate additional informaAlign Pacbio long reads using GMAP: https://github.com/PacificBiosciences/cDNA_primer/
wiki/Aligner-tutorial:-GMAP,-STAR,-BLAT,-and-BLASR
5
Align RNA-seq short reads using GMAP: https://github.com/juliangehring/GMAP-GSNAP
4
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tion into bioinformatic models for consolidating the results. This extra information
could be from other sequencing platforms, from technical or biological replicates, from
databases containing expert knowledge, etc.
This dissertation will cover three critical issues in RNA-seq modeling and model
assessments, and in each case, the problem is solved by incorporating additional
information. Chapter 2 discusses how to assess de novo assembly methods and de novo
assembly evaluation methods using a third generation sequencing technology; Chapter
3 discusses how to improve the transcript quantifcation and DE isoform identifcation
by capturing the shared information from biological replicates; Chapter 4 discusses
a joint pathway and gene selection model that incorporates pathway structures from
an expert database.
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2. CHAPTER 2. ASSESSMENTS ON RNA-SEQ DE NOVO
ASSEMBLY BY PACBIO LONG READ SEQUENCING
2.1

Abstract
RNA-Seq de novo assembly is an important method to generate transcriptomes

for non-model organisms before any downstream analysis. Given many great de novo
assembly methods developed by now, one critical issue is that there is no consensus on
the evaluation of de novo assembly methods yet. Therefore, to set up a benchmark for
evaluating the quality of de novo assemblies is very critical. Addressing this challenge
will help us deepen the insights on the properties of di˙erent de novo assemblers and
their evaluation methods, and provide hints on choosing the best assembly sets as
transcriptomes of non-model organisms for the further functional analysis.
In this article, we generate a “real time” transcriptome using PacBio long reads
as a benchmark for evaluating fve de novo assemblers and two model-based de novo
assembly evaluation methods. By comparing the de novo assemblies generated by
RNA-Seq short reads with the “real time” transcriptome from the same biological
sample, we fnd that Trinity is best at the completeness by generating more assemblies
than the alternative assemblers, but less continuous and having more misassemblies;
Oases is best at the continuity and specifcity, but less complete; The performance of
SOAPdenovo-Trans, Trans-ABySS and IDBA-Tran are in between of fve assemblers.
For evaluation methods, DETONATE leverages multiple aspects of the assembly set
and ranks the assembly set with an average performance as the best, meanwhile the
contig score can serve as a good metric to select assemblies with high completeness,
specifcity, continuity but not sensitive to misassemblies; TransRate contig score is
useful to remove misassemblies, and TransRate can optimize the assembly set by
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fltering out the assemblies with low contig scores, yet often the assemblies in the
optimal set is too few to be used as a transcriptome.

2.2

Introduction
With the rapid development of sequencing technology, transcriptome assembly

by RNA-Seq short reads has become increasingly important in many felds, such as
plant science (Brereton et al., 2016; Ranjan et al., 2014), animal science (Moreton
et al., 2014) and disease related studies (Mittal and McDonald, 2017; Mamrot et al.,
2017; Wang et al., 2015). Current transcriptome assembly methods mainly fall into
three categories: reference-based assembly, de novo assembly and a hybrid assembly
that merges the above two (Martin and Wang, 2011). For non-model organisms
with no available reference genome or transcriptome, de novo assembly becomes the
only choice to determine the transcriptome before any downstream analysis. Many
de novo assembly methods have been developed, however, there is no consensus on
how to evaluate these methods. Therefore, establishing a reliable benchmark for
understanding the property of each de novo assembly tool has become a critical issue
(Moreton et al., 2015).
Recently, powerful tools, such as Trinity (Grabherr et al., 2011), Oases (Schulz
et al., 2012), SOAPdenovo-Trans (Xie et al., 2014), Trans-ABySS (Robertson et al.,
2010), and IDBA-Tran (Peng et al., 2013), have been developed for de novo assembly of transcriptomes from RNA-Seq short reads. From the data perspective, when
evaluating de novo assembly methods, researchers can either simulate RNA-Seq short
reads base on a known reference genome or transcriptome (O’Neil and Emrich, 2013),
or use real RNA-Seq datasets and evaluate the performance of assemblers by comparing the assemblies with the reference transcriptome or the transcriptome of a related
species (Honaas et al., 2016; Wang and Gribskov, 2017). In the frst case, even though
it is convenient to control the properties of simulated data, such as the expression
levels of transcripts, the sequencing error rate , the sequencing depth and etc, the
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simulated data cannot completely represent the real data. In the latter case, the evaluation heavily relies on the quality of the reference transcriptome. Nevertheless, the
expressed transcripts may even vary among biological replicates or di˙erent tissues
(Melé et al., 2015). The presence of assemblies that are missed in the reference transcriptome does not necessarily mean that those assemblies are misassemblies. The
novel transcript could be representing mutated or fusion transcripts that hasn’t been
annotated in the reference. Similarly, the absence of assemblies compared with the
reference transcriptome does not necessarily indicate incompleteness of an assembly.
It could be that the transcripts that are not expressed in a particular sample. Even
though the reference transcriptome is well annotated for a species, e.g., Homo sapiens,
the reference transcriptomes still vary between di˙erent instititional sites (Ensembl
and RefSeq) and versions still exist, which complicate the issue from another perspective (Section 2.4.1).
Two types of methods are used for assessing de novo assemblies: metrics-based
methods and model-based methods. However, without a reference transcriptome,
metrics-based methods can only provide an empirical description rather than an assessment of the quality of the assemblies, such as the total number and the length
information of assemblies. With a reference transcriptome, the metrics-based methods have the ability to comprehensively evaluate the accuracy, completeness, continuity, and misassembly rate of the assemblies. However, this analysis is based on
the assumption that the reference transcriptome is complete and reliable (Martin and
Wang, 2011; Bushmanova et al., 2016). Model-based methods, such as DETONATE
(Li et al., 2014a) and TransRate (Smith-Unna et al., 2016), focus on how well the assemblies can be explained by the read evidence. However, each model-based method
has its own defnition of the “optimal” assembly, which is inconsistent among di˙erent
models. Furthermore, model-based methods themselves are hard to evaluate if we do
not have a reliable reference transcriptome in hand.
In this study, we utilize the PacBio long read sequencing technology to generate a
“real time” transcriptome as a benchmark for assessing (1) the properties of fve com-
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monly used de novo assembly methods and (2) the e˙ectiveness of two model-based
evaluation methods. By comparing the assemblies from the short reads to the “real
time” transcriptome from PacBio long reads of the same biological sample, we eliminate the biological uncertainties to a large extent. We conclude that Trinity is best
at completeness, but assembled transcripts are less continuous and have more misassemblies than the alternative methods; Oases is best at continuity and specifcity (we
followed the nomenclature used in rnaQUAST (Bushmanova et al., 2016); the specifcity refers to the percentage of the assemblies that can be well mapped back to the
annotated transcripts), but less complete; The performance of SOAPdenovo-Trans,
Trans-ABySS and IDBA-Tran are in between. For the model-based evaluation methods, DETONATE ranks the method with all aspects having the average performance
as the best, while TransRate doesn’t penalize any downsides but only encourages the
good aspects of the assemblies; The contig scores of DETONATE can help select the
assemblies with high completeness, specifcity and continuity but not a low misassembly rate, while the contig scores of TransRate are helpful in removing misassemblies.

2.3

Methods

2.3.1

RNA-Seq datasets

The datasets we used were from the Sequencing Quality Control (SEQC)/MAQCIII Consortium, which sequenced a human brain sample by multiple platforms, including MiSeq short read sequencing and PacBio long read sequencing (Li et al.,
2014b). MiSeq generated 7.85 million paired-end reads with the length equal to 250
bp. PacBio generated 0.68 million Reads of Insert (RoIs) with an average length
equal to 1, 640 bp.
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2.3.2

Quality control for short read de novo assemblies

We frst trimmed the adapters and fltered out the low quality reads from the
MiSeq dataset using Trimmomatic (version 0.32). Adaptors and low quality reads
with average quality below 16 over a 5 base window were removed. And only trimmed
reads with length over 30 bases were used for de novo assembly. FastQC (version
0.11.2) 1 was then used to visualize the read quality before and after cleaning, shown
in Supplementary Figure 2.5.
To determine the best kmer for de novo assembly, we used Kmergenie (version
1.6982) (Chikhi and Medvedev, 2014). Kmergenie examines multiple kmers and
counts the frequency of kmers under each k. Then Kmergenie estimates the best
k value, which potentially could recover the most possible contigs. Our dataset has
the best k = 31 bp, shown in Supplementary Figure 2.6.
Cleaned reads were used for de novo assembling by fve di˙erent assemblers, including Trinity (version 2.2.0), Oases (version 0.2.08), SOAPdenovo-Trans (version
1.03), Trans-ABySS (version 1.5.1), and IDBA-Tran (version 1.1.2). All the methods
were tested under the default parameters.

2.3.3

Quality control for the “real time” transcriptome generated by PacBio
long reads

To obtain the real time transcriptome, we ran PacBio long reads through RS_IsoSeq
(v2.3.0) pipeline (Gordon et al., 2015) using default parameters. After clustering, we
fltered out the non-human genes by aligning both the full length high-quality and
full length low-quality consensus sequences to the hg19 human reference genome using
STAR (Dobin et al., 2013) and GMAP (Wu and Watanabe, 2005) as recommended
by RS_IsoSeq. The detailed steps and the number of sequences generated in each
step are shown in Supplementary Figure 2.7. Then we collapsed the aligned consensus
1

FastQC is available at: https://www.bioinformatics.babraham.ac.uk/projects/fastqc
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sequences by pbtranscript-tofu 2 with the minimum alignment identity equal to 0.85
and the minimum coverage to 0.90, as shown in Supplementary Figure 2.2.

2.4

Results

2.4.1

The real time transcriptome can be served as a reliable benchmark
for assessing de novo assemblies

Analysis of PacBio long reads with RS_IsoSeq pipeline, produced 9, 636 genes
(33, 307 transcripts). All 33, 307 transcripts were corrected versus the hg19 human
genome. 244 full length, low-quality transcripts can be aligned to the hg19 human
genome by neither STAR nor GMAP. We pooled these 33, 307 alignable sequences
and 244 unalignable sequences together, rendering 33, 551 transcripts and 9, 880 genes
in total as the “real time” transcriptome, shown in Supplementary Figure 2.7.
First, to show the relationship between the “real time” transcriptome generated
from PacBio long reads and the well annotated human transcriptomes, we drew a
Venn diagram between the reference transcriptomes from Ensembl and RefSeq and
the “real time” transcriptome using vennBLAST (Zahavi et al., 2015). Ensembl reference transcriptome has 191, 891 transcripts; RefSeq has 63, 874 transcripts; the “real
time” transcriptome has 33, 551 transcripts. In Figure 2.1, Ensembl has the most
transcripts, which almost cover RefSeq and the real time transcriptome. The real
time transcriptome is about half the size of RefSeq and largely overlaps with RefSeq.
Apparently, the three transcriptomes do not completely overlap each other, which
indicates that the evaluations on the de novo assemblies would be very di˙erent if
we chose di˙erent reference transcriptomes. Though the “real time” transcriptome
is not the most complete set of human transcripts, it derives from the same biological sample as the short reads, which eliminates the uncertainty of sample variance.
pbtranscript-tofu is available at: https://github.com/PacificBiosciences/cDNA_primer/
wiki/tofu-Tutorial-(optional).-Removing-redundant-transcripts
2
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Fig. 2.1.: The Venn diagram of three di˙erent reference transcriptomes. A is the “real
time” transcriptome. B is the RefSeq transcriptome. C is the Ensembl transcriptome.
Note that the reason that the total number of transcripts in RefSeq and the real time
transcriptome is smaller than the numbers mentioned in the text is because there are
multiple transcripts in RefSeq and the real time transcriptome aligning to the same
transcript in Ensembl.

Therefore, the real time transcriptome should be more optimal as a benchmark for
assessing short read assemblies than the other two references.
Second, we checked whether the abundance of PacBio long reads was corresponds
to that of the MiSeq short reads. If yes, it will provide another evidence that the
“real time” transcriptome generated from PacBio long reads can serve as a reliable
reference for assessing short read assemblies. A scatter plot of the ranks of the
abundances estimated by PacBio long reads, and MiSeq short reads is shown in
Figure 2.2. Each data point represents a gene from the “real time” transcriptome.
Most highly expressed genes in PacBio also have high expressions as estimated by
short reads, and lie in the right up corner. The low expression genes in PacBio have
di˙erent expression patterns, ranging from low to high as estimated by short reads,
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and lie along the bottom. This pattern is due to the di˙erent throughputs of two
sequencing technologies. PacBio has a lower sequencing thoughput than the short
read platform. Many transcripts have only one copy detected in PacBio, but these
transcripts may have many short reads sampled in MiSeq. This relationship between
the abundances of PacBio long reads and MiSeq short reads suggests that a majority
of transcripts from the “real time” transcriptome should be recovered by the short
read assembly.
In summary, the generation of the real time transcriptome agrees with both the
well annotated reference transcriptome and the real time sampling. Therefore, the
real time transcriptome can be a better benchmark for assessing short read de novo
assembling in terms of both suÿcency and specifcity.

2.4.2

Assessments on short read de novo assembly methods

Assemblies were performed by each method and for each method the number and
the length of predicted transcripts are compared. In Table 2.1, Trinity generates the
most assemblies, while Oases generates the fewest assemblies, but with longest average
length, median length and N50. The numbers of assemblies in SOAP-denovoTrans,
and IDBA-Tran are between those of Trinity and Oases. The distribution of the
assembly length in Figure 2.3 shows that the assemblers can be categorized into
three groups. Trinity tends to give more assemblies in the range of 200 − 400 bp than
alternative methods; Oases tends to give the fewest assemblies in the range of 200−400
bp but the curve gradually goes up, having the largest N50 = 1, 090 bp. Trans-ABySS,
SOAPdenovoTrans, and IDBA-Tran share very similar distributions yet IDBA-Tran
reports a slightly higher number of assemblies in the range of 300 − 400 bp than
Trans-ABySS and SOAPdenovoTrans. This fnding is consistent with the result in
(Wang and Gribskov, 2017), which tested the above assemblers using two authentic
RNA-Seq datasets from Arabidopsis thaliana. Also, by comparing the assemblies with
three reference transcriptomes in Figure 2.3, including RefSeq, Ensembl, and the “real
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The rank of PacBio sequencing depth (f=1, p=0.5)
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The rank of gene expression (FPKM) calculated by RSEM using short reads

Fig. 2.2.: Correlation between the abundance ranks of PacBio long reads and MiSeq
short reads. The gene with the lowest abundance is ranked as the frst. X-axis shows
the ranks of gene expression in Fragments Per Kilobase of transcript per Million
mapped reads (FPKM) estimated by RSEM (Li and Dewey, 2011) using MiSeq short
reads. Y-axis shows the ranks of gene counts from PacBio long reads. If a gene is
supported by 1f 5p in PacBio long read sequencing, it means this gene is supported
by one full length read and fve partial length reads in PacBio. The expression of this
gene would be given as (1+ 0.5x5) = 3.5.
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time” transcriptome, it is clear that all assemblers provide redundant assemblies; and
the redundant assemblies are mostly in the short length range.

9
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Fig. 2.3.: Cumulative curves of the assembly length from fve de novo assembly
methods. There reference transcriptomes are also plotted as quality controls.

The more short reads that can be aligned back to the assembly, the higher probability that the assembler has generated the correct assembly, if the gene expression level is not taken into account at this stage. Table 2.2 shows that Trinity,
SOAPdenovo-Trans, and Trans-ABySS have 75% − 78% short reads that can be
mapped back, while Oases and IDBA-Tran only have 56% − 59%. If we only count
the number of concordant reads (see the second column in Table 2.2), the trend is
the same as when we count the total number of aligned reads. This suggests that
Trinity, SOAPdenovo-Trans and Trans-ABySS assemblies potentially contain more

Trinity
IDBA-Tran
SOAPdenovo-Trans
Trans-ABySS
Oases

min_len
200
200
200
200
200

max_len
22,834
23,838
27,428
27,277
27,468

Total bases
332,493,521
222,727,826
181,427,977
322,119,676
149,749,751

Number of assemblies
821,870
538,261
490,473
492,286
224,847

avg_len
405
414
370
363
666

median_len
273
266
255
254
343

Table 2.1.: Metrics for the length and the total number of assemblies from fve methods.
N50
388
412
350
341
1,090
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information from the short reads than those of Oases and IDBA-Tran. However, if
we measure the number of reads mapped back per kilobase of assembly, SOAPdenovoTrans, Trans-ABySS, and Oases have about 60 − 64 short reads mapped back per
kilobase of assembly, while IDBA-Tran has 39 and Trinity has only 10. This is because, even though Trinity covers the highest number of short reads, it reports many
more predicted assemblies than the other methods.
Table 2.2.: The number of short reads that can be mapped back to the assemblies.

Trinity
SOAPdenovo-Trans
Trans-ABySS
Oases
IDBA-Tran

Total number of
read support

Number of
concordant reads

Number of reads
per 1K assmblies

11,897,117(78.45%)
11,355,630(74.88%)
11,372,597(74.99%)
9,021,448(59.49%)
8,595,231(56.68%)

3,318,984(21.89%)
2,807,074(18.51%)
2,809,522(18.53%)
2,089,026(13.78%)
1,992,794(13.14%)

9.98
62.59
63.64
60.24
38.59

The total number of read support include both the concordantly and disconcordantly mapped
reads. Concordant read support means both of the paired end reads can be mapped into an
assembly in the right orientation. The disconcordant reads mean either the paired end reads
cannot map to the same assembly or map to an assembly in a reversed manner. The number
of aligned reads per kilobases of assemblies = the total number of read support / the total
number of assemblies.

We evaluated the qualities of assemblies by aligning them back to the “real time"
transcriptome using rnaQUAST (Bushmanova et al., 2016) (version 1.4.0). We considered all main statistics reported by rnaQUAST to evaluate the quality of assemblies, including alignability, accuracy, completeness/sensitivity, specifcity, continuity,
and misassembly. The overall performance of SOAPdenovo-Trans, Trans-ABySS and
IDBA-Tran (Table 2.3,) are similar; SOAPdenovo has the highest accuracy and the
lowest number of misassemblies in fve methods. Oases and Trinity perform very
di˙erently, yet each has its own advantages. Oases has the longest average alignment
length, the best continuity, specifcity, and mean isoform coverage, but Oases assemblies are less complete at both the gene and isoform level. Trinity has the highest
completeness at both the gene and isoform level, and a slightly lower specifcity than
Oases, but a relatively poor continuity and the highest rate of misassemblies. Note
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that the specifcities are very low in all fve methods, which indicates a redundancy
of assemblies reported.

2.4.3

Assessments on model-based de novo assembly evaluation methods

There are two state-of-the-art methods having been assessed here, DETONATE
(version 1.9) and TransRate (version 1.0.1). The RSEM-EVAL module of DETONATE is used for evaluating de novo assemblies without a reference transcriptome.
The RSEM-EVAL score is the sum of three components; the likelihood estimates
how well the assemblies are explained by the mapped short reads; the assembly prior
assumes the assembly length follows a negative binomial distribution and the transcripts are independent from each other (the number of isoforms or homogenous genes
will infuence this component); the BIC penalty penalizes the prediction of too many
bases and assemblies. Table 2.4 shows that the likelihood makes the largest contribution to the RSEM-EVAL score. Consistent with Table 2.2 and 2.3, Trinity has the
highest likelihood, but the lowest assembly prior and BIC penalty, which lowers its
overall RSEM-EVAL score. On the contrary, SOAPdenovo-Trans and Trans-ABySS
do not score highly any component, which is consistent with Table 2.3, but achieve
the best overall RSEM-EVAL score, because no single component dominates the fnal
evaluation. IDBA-Tran and Oases have low RSEM-EVAL scores mainly due to the
low likelihoods, though Oases has the best assembly prior and BIC penalty, which is
also consistent with Table 2.2 and 2.3.
TransRate shows the opposite pattern compared with DETONATE. The TransRate assembly score is the geometric mean of the contig scores multiplied by the proportion of short reads that positively support the assemblies. Each contig score is the
product of four components: the nucleotide score measuring the alignment distance
between the assembly and the short reads, the coverage score measuring the fraction
of the assembly length covered by reads, the order score measuring the orientation
of the paired-end read mapping, and the segment score measuring the per-nucleotide

37
read coverage. In Table 2.5, we fnd that Oases has the highest
TransRate score.
q
� Qn
 n1
However, after optimizing an empirical target function – T =
S(C)
Rvalid ,
c=1
where S(C) is the contig score, n is the number of selected contigs, and Rvalid is the
proportion of reads that can be mapped to the selected contigs – as recommended by
TransRate, the TransRate scores of all methods greatly increase, and Trinity has the
best optimal score.

2.4.4

Contig scores can serve as a good metric for removing low quality
assemblies

In Section 2.4.2, we found that the number of predicted assemblies produced by
de novo approaches was about 15 times of the number of transcripts in the“real time”
transcriptome, on average; In Section 2.4.3, we found that a large portion of assemblies have low DETONATE and TransRate contig scores. Together, this indicates a
redundancy of assemblies. Therefore, the question is whether DETONATE and TransRate contig scores can serve as good metrics for removing low-quality assemblies.
We selected the top 40, 000 assemblies based on the DETONATE score, the TransRate score, and the FPKM of each assembly. An ideal selection would be an assembly
set with no change in completeness, but with increased specifcity and continuity, and
decreased misassembly rate, compared with the full set of assemblies. Figure 2.4
shows the comparison between the full set and the selected set of assemblies in the
completeness, specifcity, continuity and the misassembly rate. For completeness, the
database coverage rates are decreased in all selected sets compared to the full set, but
DETONATE selections show higher completeness than TransRate and FPKM. For
specifcity, DETONATE selections show a generally higher mean fraction of matched
assemblies than the full set of assemblies in all methods, but not the other two metrics.
For continuity, DETONATE selections also show a generally higher mean fraction of
isoform length assembled than the full set of assemblies; FPKM selections also have
a higher continuity than the full set in all methods, except for Trinity. For the misas-

38
sembly rate, both TransRate and FPKM selections can greatly decrease the number
of misassemblies but not DETONATE, which might because TransRate takes the
order score into account.
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Fig. 2.4.: Eÿciency to remove low quality assemblies by three di˙erent metrics,
including DETONATE contig score, TransRate contig scores and the FPKMs of contigs. Four major aspects have been evaluated by comparing the top 40, 000 selected
assemblies with the“real time" transcriptome. We evaluate the assembly quality in
terms of the completeness, specifcity, continuity, and the misassembly rate, as that in
Table 2.3. The misassembly rate is calculated as the number of misassemblies divided
by the number of assemblies.

39
Table 2.3.: Evaluations of assemblies from fve de novo assembly methods by comparing with the “real time" transcriptome. We followed the nomenclatures used in
rnaQUAST.
Alignment
Number of alignments (hit=50bp)
Avg aligned length (bp)
Accuracy
Avg mismatches (bp) per 1K alignment
Completeness/Sensitivity
Gene level
Number of > 50% covered genes
Number of > 95% covered genes
Isoform level
Number of > 50% covered isoforms
Number of > 95% covered isoforms
Database coverage
Mean isoform coverage
Specifcity
Number of > 50% matched assemblies
Number of > 95% matched assemblies
Mean fraction of assemblies matched
Unannotated assemblies
Continuity
Gene Level
Number of > 50% assembled genes
Number of > 95% assembled genes
Isoform Level
Number of > 50% assembled isoforms
Number of > 95% assembled isoforms
Mean isoform continuity
Misassemblies

SOAPdenovo-Trans

Trans-ABySS

IDBA-Tran

Oases

Trinity

489,823(99.87%)
367.8

491,598(99.86%)
360.1

537,458 (99.85%)
408.8

224,564(99.87%)
649.8

820,611(99.85%)
368.4

1.4

1.6

1.7

1.5

3.0

6,390(66.31%)
2,805(29.11%)

6,385(66.26%)
2,851(29.59%)

6,539(67.86%)
2,796(29.02%)

6,193(64.27%)
2,845(29.52%)

6,895(71.55%)
3,085(32.02%)

7,020(21.08%)
2,865(8.60%)
24.1%
48.8%

6,952(20.87%)
2,885(8.66%)
23.8%
47.9%

7,964(23.91%)
2,974(8.93%)
26.4%
52.7%

7,726(23.20%)
3,104(9.32%)
25.5%
59.9%

10,396(31.21%)
3,423(10.28%)
33.7%
53.3%

16,175(3.30%)
10,391(2.12%)
3.4%
459,792(93.74%)

16,309(3.31%)
10991(2.23%)
3.4%
458,408 (93.12%)

24,250(4.51%)
13003(2.42%)
4.5%
492,515(91.50%)

19,694(8.76%)
9505(4.23%)
8.6%
192,489(85.61%)

62,758(7.64%)
35316(4.30%)
7.6%
708,017 (86.14%)

5,228(54.25%)
2,270(23.56%)

5,243(54.41%)
2,243(23.28%)

5,266(54.65%)
2,123(22.03%)

5,370(55.73%)
2,381(24.71%)

4,967(51.55%)
1,800(18.68%)

5,604(16.83%)
2,313(6.94%)
42.4%
3,233(0.66%)

5,561(16.70%)
2,268(6.81%)
41.5%
5,859(1.19%)

6,287(18.88%)
2,265(6.80%)
45.5%
9,874(1.83%)

6,663(20.00%)
2,605(7.82%)
54.3%
4,332(1.93%)

7,160(21.50%)
2,002(6.01%)
42.9%
30,915(3.76%)

• Completeness/sensitivity is calculated by aligning the assemblies to the genes/isoforms in the
database, showing how completely the assemblies can cover the database.
• Specifcity is calculated by aligning the isoforms/genes in the database to the assemblies,
showing how specifc or redundant the assemblies are in the database.
• Continuity is always calculated using the longest assemblies that can continuously mapped
to the genes/isoforms in the database, showing whether the assemblies are integral.
• Misassemblies are confrmed by both GMAP and BLASTN, meaning partial alignments from
the one assembly can be equally well mapped to di˙erent locations in the database.
• Genes/isoforms mean the transcripts from the real time transcriptome. Assemblies means
the de novo assemblies generated by each assembler.
• Gene/isoform coverage is a percentage calculated as the number of bases on the gene/isoform
covered by the assemblies divided by the length of this gene/isoform.
• x% covered genes/isoforms means the number of genes/isoforms that have at least x%
gene/isoform coverage.
• Database coverage means the total number of bases covered by assemblies divided by the
total length of all isoforms in the database.
• The matched fraction of each assembly is calculated as the number of matched bases on the
assembly divided by the length of this assembly.
• x% matched assemblies means the total number of assemblies that have at least x% matched
fraction.
• Unannotated assemblies mean the total number of assemblies that do not cover any isoform
from the database.
• Gene/isoform continuity is also a percentage calculated as the number of bases on the
gene/isoform covered by the longest continuous assembly divided by the length of this
gene/isoform.
• x% assembled genes/isoforms means the number of genes/isoforms that have an at least x%
gene/isoform continuity.
Dark green: the best performance; Light green: good performance, slightly lower than the
best, but better than the rest methods; Red: the lowest performance. For those having no
color marked, their performance are comparable to each other, but obviously better than the
red and worse than the green.

Trans-ABySS
-3,016,249,561
-247,841,006
-3,899,242
-3,267,989,809

IDBA-Tran
-3,238,791,356
-308,900,873
-4,263,395
-3,551,955,624

Oases
-3,225,800,940
-207,358,450
-1,780,946
-3,434,940,336

Trinity
-2,841,562,473
-461,191,586
-6,509,768
-3,309,263,827

* The RSEM-EVAL score is the sum of three components, including the likelihood, the assembly prior and the BIC penalty for
each assembly set.

Likelihood
Assembly prior
BIC penalty
RSEM-EVAL score *

SOAPdenovo-Trans
-3,001,246,561
-251,577,741
-3,884,882
-3,256,709,184

Table 2.4.: DETONATE RSEM-EVAL scores for fve de novo assembly methods.
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TransRate score
Optimal score
Potential Bridges

SOAPdenovo-Trans
0.00173
0.02787
2,546

Trans-ABySS
0.00166
0.02757
1,129

IDBA-Tran
0.00087
0.00877
8,014

Oases
0.00271
0.01748
5,379

Trinity
0.00221
0.03122
42,296

Table 2.5.: TransRate assembly and the assembly scores after optimization for fve de novo assembly methods. The
potential bridges show the number of potential links between contigs that are supported by the reads.

41

42
2.5

Discussion
In this study, we propose a reliable benchmark – a real time transcriptome, pro-

duced by PacBio long read sequencing – for assessing the de novo assembly and
evaluation methods. As opposed to other de novo assembly assessment strategies,
which either simulate RNA-Seq data or utilize well annotated reference transcriptome as a ground truth for real data, our study takes the advantage of sequencing
the same biological sample using both the short read and long read technologies to
eliminate the biological uncertainty. The real time transcriptome relies on both the
well annotated reference transcriptome and the real time sampling, thus, the real time
transcriptome can serve as a better reference for assessing de novo assemblies than
the alternative simulation or a reference transcriptome.
By comparing the de novo assemblies from fve commonly used methods to the
real time transcriptome, we fnd that the properties of the tested assemblers vary
signifcantly. For instance, Trinity has the highest read mapping rate (shown in
Table 2.2), and the best completeness, but generates too many short assemblies in the
range between 200 − 400 bases (shown in Figure 2.3). This makes Trinity assemblies
less continuous, and potentially increasing the number of assemblies that can be
linked by short reads (shown in Table 2.5). Trinity also has the highest misassembly
rate of the fve methods (shown in Table 2.3). An improvement to Trinity would
be to decrease the number of misassemblies while increasing the continuity. Oases
generally generates the longest and the fewest assemblies in all fve methods (shown
in Table 2.1), which gives it the best continuity and specifcity (shown in Table 2.3).
However, Oases has a low read mapping rate (shown in Table 2.2), which makes
it less complete than the other methods. An improvement to Oases would be to
increase the completeness of the assemblies. The performance of SOAPdenovo-Trans,
Tran-AByss, and IDBA-Tran are very similar, but SOAPdenovo-Trans has the lowest
number of mismatches and misassemblies of the fve methods (shown in Table 2.3).
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Because of the overall redundancy of de novo assemblies in all the methods, DETONATE and TransRate can serve as good metrics to evaluate and remove low-quality
assemblies, but with di˙erent patterns. The DETONATE assembly score mainly considers the read mapping rate, the independence of transcripts, the total number of
assemblies, and the number of assembled bases when evaluates the assemblies. DETONATE ranks the method with no extreme disadvantages in the above aspects as the
best (shown in Table 2.4). The TransRate assembly score is an empirical function
that takes many di˙erent aspects into account, mainly including the mapping accuracy, the mapping orientation, the mapping depth, the mapping coverage, and the
fraction of mapped reads. By taking the product of the frst four terms as the contig
score, TransRate actually treats the frst four aspects equally, then weights the contig
score by the fraction of mapped reads. TransRate only encourages the advantages
but doesn’t penalize the disadvantages of the assembly, as the way DETONATE does.
The optimization of the TransRate assembly score is a good way to select the best
quality assemblies, but the number of selected assemblies is often low, and cannot be
controlled by users.
Both DETONATE and TransRate provide contig scores as an evaluation for each
assembly. The contig scores can be used as metrics for removing redundant low quality
assemblies. When the top 40, 000 assemblies ranked by DETONATE, TransRate
and FPKM are examined, we fnd that the DETONATE contig score can e˙ectively
remove the redundant assemblies while keeping a high completeness and continuity
rate, but not be able to remove misassemblies. The TransRate contig score is very
sensitive in removing misassemblies but not helpful in the completeness, specifcity
and continuity.
There is weakness in this study. For instance, only one dataset has been tested
here, because it is not very easy to obtain the datasets which have been sequenced
by both short read and long read technologies. It would be better to include further
benchmark datasets to eliminate any bias from the sequencing platforms or organisms. Also, we evaluated the assemblies from several major perspectives, including
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length, the total number of assemblies, the read mapping rate, completeness, specifcity, continuity and misassembly, by comparing the assemblies with the real time
transcriptome. There may be additional perspectives that the model-based evaluation
methods take into account, but are not included in our metrics.

2.6

Supplementary materials

Fig. 2.5.: MiSeq read quality visualization by FastQC before and after trimming.
(A) and (B) are the positional qualities of forward and backward reads in the raw
dataset. (C) and (D) are the positional read qualities of forward and backward reads
after trimming.
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Fig. 2.6.: Kmergenie shows kmer = 31bp is the best choice for short read assembly.
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Fig. 2.7.: The fowchart of processing PacBio long reads into real time transcriptome. We begin from the .bax.h5 raw data. The frst step is classifcation, namely
to classify Reads of Inserts (RoIs) into full-length and non-full-length RoIs based on
the adaptors, meanwhile removing the chimeric RoIs. The second step is clustering,
namely to cluster RoIs into consensus, while each consensus can be viewed as a transcript. The third step is collapsing and correction, namely to align the consensus
sequences back to the reference genome and get the real time transcriptome.
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Fig. 2.8.: Selections of the thresholds for coverage and identity when align the
consensus sequences back to the human reference genome. Because the coverage and
identity are the only parameters the user has to set when running the collapse step in
pbtranscript-tofu.py, and these parameters will eventually infuence the numbers of
transcripts and genes in the real time transcriptome, we carefully select the values of
these two parameters. (A) and (B) show the number of transcripts and genes in the
real time transcriptome when we set di˙erent coverages and identities, respectively.
Note that when the coverage is from 0.90 to 0.95, more transcripts/genes will be
dropped out than the previous columns, which indicates many consensus sequences
having a coverage between 0.90 and 0.95. To keep as much information from PacBio
long reads as possible, we consider coverage = 0.9 is a long enough to represent
a transcript/gene. Similarly for identity, when identity is from 0.85 to 0.90, more
transcripts/genes will be dropped out than the previous columns. Taking the facts
that the error rate of PacBio sequencing was about 10%-15% in 2013 and the average
length of consensus sequence (1, 640 bp) was long enough to align the consensus
sequence to the right position on the genome into account, we choose identity = 0.85
in our dataset.
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3.1

Abstract

Motivation: High-throughput mRNA sequencing (RNA-Seq) is a powerful tool for
quantifying gene expression. Identifcation of transcript isoforms that are di˙erentially expressed in di˙erent conditions, such as in patients and healthy subjects, can
provide insights into the molecular basis of diseases. Current transcript quantifcation approaches, however, do not take advantage of the shared information in the
biological replicates, potentially decreasing sensitivity and accuracy.
Results: We present a novel hierarchical Bayesian model called DEIsoM (Di˙erentially
Expressed Isoform detection from Multiple biological replicates) for identifying DE
(Di˙erentially Expressed) isoforms from multiple biological replicates representing
two conditions, e.g., multiple samples from healthy and diseased subjects. DEIsoM
frst estimates isoform expression within each condition by (1) capturing common patterns from sample replicates while allowing individual di˙erences, and (2) modeling
the uncertainty introduced by ambiguous read mapping in each replicate. Specifcally,
we introduce a Dirichlet prior distribution to capture the common expression pattern
of replicates from the same condition, and treat the isoform expression of individual
replicates as samples from this distribution. Ambiguous read mapping is modeled
as a multinomial distribution, and ambiguous reads are assigned to the most probable isoform in each replicate. Additionally, DEIsoM couples an eÿcient variational
inference and a post-analysis method to improve the accuracy and speed of identifcation of DE isoforms over alternative methods. Application of DEIsoM to an HCC
(Hepatocellular Carcinoma) dataset identifes biologically relevant DE isoforms. The
relevance of these genes/isoforms to HCC are supported by PCA (Principal Component Analysis), read coverage visualization, and the biological literature.
Availability: The software is available at : https://github.com/hao-peng/DEIsoM
Contact: pengh@purdue.edu
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3.2

Introduction
RNA-seq is a powerful tool for investigating the transcriptomes of various organ-

isms. There are many complex issues in RNA-seq and transcriptome analysis ranging
from RNA-seq read correction (Le et al., 2013), transcriptome assembly (Martin and
Wang, 2011) to alternative splicing and gene fusion detection (Ozsolak and Milos,
2011). However, one of the most fundamental issues is to quantify and identify isoforms di˙erentially expressed in two conditions, while each containing multiple replicates. Most DE isoform quantifcation methods treat each replicate independently,
ignoring the fact that, because the underlying biological mechanism is the same in
a given condition, the replicates tend to share similar expression patterns. DEIsoM
improves DE isoform identifcation and quantifcation by catching the information
shared between replicate samples; rather than separately estimating the isoform expression for each replicate, it captures the common expression pattern of the whole
condition in one single model.
Although many computational tools have been developed for quantifying and identifying DE isoforms using RNA-seq data, nearly all approaches estimate the isoform
abundance in each replicate separately, and do not attempt to actively capture the
aforementioned shared information. For instance, MISO (Mixture of ISOforms) (Katz
et al., 2010) infers the isoform fractions for each replicate and evaluates the DE of
every pair of replicates using the Bayes Factor, not considering replicates as a group.
Additionally, MISO is slow due to its use of MCMC sampling, which is computationally challenging to adapt to the rapid growth in the amount of RNA-seq data
(Kakaradov et al., 2012). DRIMSeq (a Dirichlet-Multinomial framework) (Nowicka
and Robinson, 2016) infers the isoform fractions for each replicate in a DirichletMultinomial model with a fxed hyperparameter and evaluates DE between two conditions by likelihood ratio test. Cu˜inks (Trapnell et al., 2012) quantifes the isoform abundance in individual replicates by maximum a posteriori (MAP) and detects
DE isoforms by the hypothesis test based on Jensen-Shannon divergence. RSEM
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(RNA-Seq by Expectation Maximization) (Li and Dewey, 2011) estimates isoform
abundance for each replicate using an Expectation Maximization (EM) algorithm.
EBSeq (Empirical Bayesian Seq) (Leng et al., 2013) then takes the expected counts
from all replicates to ft a joint model and estimates the probability of DE for each
isoform between multiple conditions. However, the variance of the expected counts
stemming from ambiguous read mapping is simply lost in this process, compromising
the DE isoform detection. BitSeq (Bayesian inference of transcripts from Sequencing
data) (Glaus et al., 2012) (Hensman et al., 2015) estimates the per condition mean
isoform abundance from multiple replicates. However, BitSeq accomplishes this estimation in two stages rather than in an integrated model, which could potentially lose
information when the “pseudo-data” from each ftted model in stage 1 is fed to the
conjugate normal-gamma model in stage 2. Some other models do take the strategy of
utilizing the shared information from multiple biological replicates, such as rMATS
(Shen et al., 2014), and MAJIQ (Vaquero-Garcia et al., 2016). However, they are
both exon-centric, quantifying and identifying alternative splicing at the exon level
not the isoform level.
Here, we present DEIsoM, a hierarchical Bayesian model for quantifying and identifying DE isoforms between two conditions. Other than estimating the isoform abundance in each replicate separately, DEIsoM actively captures the shared information
of perconditioned replicates in one principle framework. Specifcally, DEIsoM uses
a Dirichlet prior distribution to capture the shared information among replicates in
each condition, and implements a fast VB (Variational Bayesian) method to gain
computational eÿciency instead of MCMC sampling when computing the posterior
distributions of isoform fractions. Figure 3.1(A) shows a typical design for an RNASeq experiment with three replicates in each condition. Because we assume that the
replicates in one condition share the same underlying biological mechanism, their
expression patterns tend to be the same within a certain sample variance. We capture this common pattern through a Dirichlet prior with a tracable and e˙eciently
updated hyperparameter. Additionally, we evaluate the DE isoforms by computing
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the KL (Kullback–Leibler) divergence between the posterior distributions of the two
conditions, which is intrinsically fast in our model. Figure 3.1(B) gives a qualitative
idea of how KL divergence is used to evaluate DE; the DE level is represented as the
non-overlapping areas between the two posterior distributions.
Simulations in Section 3.4 demonstrate the superior performance of DEIsoM over
alternative methods for quantifying and predicting DE isoforms, as well as the improved computational speed of VB method compared to MCMC sampling. Furthermore, on a real HCC dataset (Section 3.5), DEIsoM identifes HCC relevant DE
isoforms which are supported by PCA, read coverage visualization, and the biological
literature.
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Fig. 3.1.: DEIsoM estimation concept. (A) shows a typical RNA-Seq experimental
setting targetted by DEIsoM. There are two conditions, each of which comprises three
replicates shown as pie charts representing the expression fractions of two isoforms
of a particular gene. We assume that the replicates in one condition are more likely
to share a similar expression pattern, which will be modelled by the Dirichlet prior
distribution. (B) shows the posterior distribution of fractional isoform expression
for each condition. The DE level of the isoform between two conditions can be
represented by the non-overlapping regions (purely blue and yellow) under the two
curves. In other words, the smaller the overlapping region is, i.e., the more distinct
the two posteriors, the more di˙erentially expressed the isoforms of this gene. We
measure this distinction by KL divergence, which is a widely recognized method to
capture the di˙erence between two probability distributions.
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3.3

Methods
DEIsoM consists of three parts: the hierarchical graphical model for isoform quan-

tifcation (Section 3.3.1), the VB algorithm for model estimation (Section 3.3.2) and
the identifcation of DE isoforms between two conditions (Section 3.3.3).

3.3.1

Model

Suppose we have collected RNA-seq data from M replicates in each condition.
For the mth replicate, there are in total N (m) paired-end reads that can be aligned to
a given gene with K isoforms. Here, we utilize the previous annotated or assembled
(m)

isoforms, so K is known for each gene. We use a K-dimensional binary vector, Rn , to
represent the read alignment to isoforms. If the nth read from the mth replicate maps
(m)

(m)

to the k th isoform, the k th element of Rn , Rn,k , is set to be 1, and 0 otherwise.
The unsequenced fragment length between the nth paired-end reads is denoted as
(m)

λn

(m)

(m)

= [λn,1 , . . . , λn,K ].

First, we model how a read is generated from an isoform. We use a binary ran(m)

dom variable Zn,k to represent whether the nth read of the mth replicate is actually
(m)

generated from the k th isoform. We call Zn,k the latent read origin. Although a read
can map to multiple isoforms, it can only be sequenced from one isoform. Therefore,
(m)

is a K-dimensional vector with exactly one element equal to 1 and all the othP
(m)
(m)
th
ers equal to 0, where K
replicate, Zn
k=1 Zn,k = 1. We assume that for the m
Zn

(m)

follows a multinomial distribution p(Zn |ψ (m) ), where ψ (m) is a K-dimensional vector representing the fractions of isoforms in the mth replicate for a given gene. Thus,
P
(m)
(m)
ψk ∈ [0, 1] for all k and K
= 1. The fractions of isoforms {ψ (m) }m=1..M can
k=1 ψk
vary among replicates, but we assume that the replicates all follow the same Dirichlet
prior distribution p(ψ|α) in each condition. Di˙erent from MISO, which uses one
fxed prior p(ψ) for each replicate, DEIsoM shares the same prior among replicates.
The underlying reason is that the distributions of isoforms from di˙erent replicates of
the same condition are not independent, but share some common patterns. DEIsoM
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summarizes the shared information in the hyperparameter α. In Section 3.3.2, we
will further explain how the hyperparameter α is updated using the information from
all replicates.
(m)

We assume that the observed read alignments Rn,k and the unsequenced fragment
(m)

length λn,k are conditionally independent given the corresponding latent read origin
Z(m) and some fxed parameters Θ:
(m)

(m)

(m)

(m)

(m)

(m)

p(Rn,k , λn,k |Zn,k , Θ) = p(Rn,k |Zn,k , Θ)p(λn,k |Θ)
where Θ includes lk , L, µ and σ 2 . lk is the length of the k th isoform; L is the
(m)

sequenced read length; µ and σ 2 are the mean and variance of λn
frst part,

(m)
(m)
p(Rn,k |Zn,k , Θ),

respectively. The

represents the probability that a read can be aligned to

a specifc region of the k th isoform conditioned on whether it is generated from this
isoform. If the nth read is generated from the k th isoform, this read is assumed to be
uniformly generated from one of all the possible positions in this isoform. Otherwise,
(m)
(m)
(m)
(m)
p(Rn,k |Zn,k , Θ) is 0. The number of all possible positions is ˜ln,k = lk −(2L+λn,k )+1,

Then the conditional distribution is:
(m)
p(Rn,k

⎧
⎨ 1/˜l(m)
n,k
(m)
= 1|Zn,k , Θ) =
⎩
0

(m)

if Zn,k = 1
otherwise.

(m)

The second part, p(λn,k |Θ), is the probability of observing a paired-end read with
(m)

unsequenced length λn , which follows a normal distribution with mean µ and variance σ 2 . Both µ and σ 2 can be given or estimated from the aligned RNA-seq data.
As a result, we have the following generative process for each of M replicates (Figure
3.2):
1. ψ (m) ∼ Dirichlet(α)
2. For each of N (m) reads:
(m)

(a) Zn

∼ Multinomial(1, ψ (m) )
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(m)

(m)

(m)

(b) Rn,k ∼ p(Rn,k |Zn,k , Θ)
(m)

(c) λn,k ∼ Normal(µ, σ 2 )

(m)
n

Ψ(m)

α

Θ

Zn(m)
Rn(m)
n = 1 .. N(m)
m = 1 .. M

Fig. 3.2.: The graphical model representation of DEIsoM.

3.3.2

Estimation

To compute the posterior distribution of isoform fractions and read assignments,
p(ψ, Z|R, α, Θ) =

p(ψ, Z, R|α, Θ)
p(R|α, Θ)

we need to compute the denominator:
p(R|α, Θ) =

YZ

p(ψ (m) |α)

m
(m)
(m)
(m)
p(Rn,k , λn,k |Zn,k

YXh
(m)
(m)
p(Zn,k = 1|ψk )×
n

k

i
= 1, Θ) dψ (m)

which is computationally intractable, so we have to use approximate inference techniques, such as Markov Chain Monte Carlo (MCMC) sampling method or Variational
Bayesian method. Classical MCMC methods may take a long time to converge due
to the high correlation between the latent variables (Section 3.4.2). The Variational
Bayesian method (Jordan et al., 1999) tends to be faster and better scalable to large
data for many graphical models. The VB algorithm approximates the intractable
posterior p by a proposed distribution q, where q belongs to a family of distributions
controlled by the variational parameters. We can optimize the variational parameters
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to minimize the Kullback-Leibler divergence between q and the posterior p, KL(q||p).
This is equivalent to maximizing a variational evidence lower bound. In such a way,
the inference problem is cast to an optimization problem, which can be eÿciently
solved by gradient-based optimization algorithms.
For our model, we propose a family of variational distributions, which has the
form:
q(ψ, Z) =

Y

q(ψ (m) ; β (m) )

Y

m

(m)
q(Z(m)
n ; rn ),

n
(m)

(m)

where q(ψ (m) ; β (m) ) is a Dirichlet distribution parameterized by β (m) and q(Zn ; rn )
(m)

is a multinomial distribution parameterized by rn .
We use the following iterative variational EM algorithm updates to fnd the optimal parameters for our model:
(m)

1. (E-step) For each replicate, estimate the variational parameters rn , β (m) ;
2. (M-step) Maximize the variational evidence lower bound with respect to the
hyperparameter α.
In E-step, we estimate the posterior distribution using a very commonly used algorithm, coordinate ascent variational inference (CAVI) (Bishop, 2006). We iteratively
update:
(m)

(m)
rn,k

ρn,k

= PK

(m)
l=1 ρn,l

and

(m)
βk

= αk +

(m)
N
X

(m)

rn,k

(3.1)

n=1

where
(m)
ρn,k




=p
= 1, Θ ×
"
#
K
X
(m)
(m)
exp z(βk ) − z(
βl )
(m)
(m)
(m)
Rn,k , λn,k |Zn,k

l=1

(3.2)
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and z denotes the digamma function which is the derivative of the log-gamma function.
In M-step, we can use the Newton-Raphson method to update the hyperparameter α. This method is widely used for parameter estimation of models with Dirichlet
priors (Ronning, 1989; Minka, 2000; Blei et al., 2003). Here, we initialize the hyperparameter α = 1. The Newton-Raphson method fnds the stationary point of an
objective function using the iterative updates:
(3.3)

αnew = αold − H(αold )−1 g(αold )

where g and H denote the gradient and the Hessian matrix of the objective function
respectively. However, some new αk may become non-positive during the iterative
updates, which is invalid for Dirichlet distributions. Therefore, instead of working on
α directly, we update log(α) frst and then take the exponential of it. Let γ = log(α).
The gradient and the Hessian of the variational lower bound with respect to γ can
be computed as:
!
K
X
z(
αl ) − z(αk ) αk +

gk (γ) =M

l=1
M
X

K
X
(m)
(m)
z(βk ) − z(
βl )

αk

m=1

(3.4)

l=1
K
X
0
z(
αl )αi αj

Hi,j (γ) = M

!

!
+ σ(i, j)Δi (α)

(3.5)

l=1

where we defne σ(i, j) = 1 if i = j, otherwise σ(i, j) = 0, z0 is the trigamma function,
and
Δi (α) = M

z(

K
X

!
αl ) − z0 (αi )αi − z(αi ) αi

l=1

+ αi

M
X
m=1

(m)
z(βi )

− z(

K
X
l=1

!
(m)
βl )

(3.6)
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A drawback of taking the logarithm is that we can no longer use the special structure
of Hessian to compute H −1 g eÿciently as in Blei et al. (2003). Since Hessian computation can be expensive for large K, we update γ with L-BFGS method using the
gradient only. Updates for α will terminate when the maximum number of iterations
is reached or the change in evidence lower bound is smaller than our threshold.

3.3.3

Identifcation

The DE level of an isoform can be represented as the di˙erence between the
posterior distributions of isoform fractions under two conditions. As used in the
Variational Bayesian method, KL divergence measures the di˙erence between any
two distributions. Therefore, we compute the KL divergence between the posterior
distributions of isoform fractions under the two conditions to evaluate the DE level of
the isoforms. A higher KL divergence implies that the isoforms of this gene are more
di˙erentially expressed under the two conditions. Specifcally, we train the model and
estimate the posterior distribution p(ψ|R, α, Θ) with data from healthy and diseased
conditions respectively. As described in Section 3.3.2, although the exact posterior
distribution cannot be computed, we use the approximate posterior distributions from
two conditions, q(ψ; β) and q 0 (ψ 0 ; β 0 ), to compute the KL divergence. Because q(ψ m )
or q 0 (ψ m ) are independent Dirichlet distributions, the KL divergence, DKL can be
computed analytically as:
0

DKL (q||q ) =

M n
X

PK

k=1
log PK

(m)

βk

K
X

0(m)

k=1

log

Γ(βk

)

+
(m)
Γ(β
)
m=1
k=1
k
K
K
X (m)
X (m) o
0(m)
(m)
[βk − βk ][z(βk ) − z(
βl )]
0(m)

k=1 βk

+

(3.7)

l=1

To remove the asymmetry of DKL between two conditions, we further compute the
Jensen-Shannon divergence DJS = 21 [DKL (q||q 0 ) + DKL (q 0 ||q)].
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3.4

Simulations
In this section, we present four simulation studies to test that (1) whether DEIsoM

benefts from the shared information from the multiple biological replicates compared
with alternative methods; (2) whether the VB inference speeds up the computation
without loss of accuracy; (3) whether DEIsoM is robust to di˙erent simulation settings; (4) whether the quantifcation of DEIsoM outperforms alternative methods
under a more realistic setting.

3.4.1

Comparison of fve methods on synthetic data

To test whether the shared information contributes to DE isoform detection, we
generate synthetic data and compare DEIsoM with four commonly used programs:
Cu˜inks (v2.2.1), MISO (v0.5.3), RSEM (v1.2.30), and BitSeqVB (v0.7.5). The
synthetic data are generated as follows. We frst randomly select 200 genes (1395
isoforms) from the annotation of chromosome 1 in the hg19 human reference genome,
in which 100 genes are labeled as containing DE isoforms and the rest are non-DE. To
make the synthetic data more realistic, we sample the expression levels of genes from a
log-normal distribution (Gierli«ski et al., 2015). Isoform fractions are generated from
a symmetric Dirichlet distribution with α = 1, which means the chance of sampling
any fraction of isoforms is equally probable. For instance, if there are three isoforms,
the probability of sampling the isoform fraction as (0.1, 0.2, 0.7) is the same as (0.2,
0.3, 0.5). For DE isoforms, we draw two di˙erent samples for two conditions respectively; for non-DE, we draw only one sample shared by both conditions. To model the
variation among replicates, we add Gaussian noise with a standard deviation equal to
10% of the expression level of each replicate. According to Standards, Guidelines and
Best Practices for RNA-Seq V1.01 , the number of paired-end RNA-Seq reads used in
current studies is around 30 million per replicate. And for each tissue, it is generally
Standards, Guidelines and Best Practices for RNA-Seq V1.0 can be found at: https://genome.
ucsc.edu/ENCODE/protocols/dataStandards/ENCODE_RNAseq_Standards_V1.0.pdf

1

64
expected more than 10, 000 genes are expressed (Consortium, 2015). Following the
above empirical read numbers, we generate 600, 000 RNA-Seq reads for 200 genes
using RNASeqReadSimulator

2

for each of fve replicates in both conditions, using

default settings.3 To test the robustness of DEIsoM, we repeat the above simulation
process 10 times. For RSEM, BitSeq, MISO, and DEIsoM, the simulated reads are
mapped back to the reference transcriptom using Bowtie2 (Langmead and Salzberg L,
2012). For Cu˙di˙, the reads are mapped back to the hg19 reference genome using
Tophat (Trapnell et al., 2009). The machine used to run all experiments has two
8-Core Intel Xeon-E5 processors and 64GB memory.
First, we compare the quantifcation performance of DEIsoM with MISO, Cu˙di˙,
RSEM and BitSeqVB in terms of the correlations between the predicted isoform
fractions and the ground truth on the synthetic data. Figure 3.3 (A) summarizes
the means and the standard errors of the correlation coeÿcients in 10 replicates.
They show that the correlation coeÿcients in DEIsoM is higher than the alternative
methods.
Second, we compare the DE isoform identifcation performance of DEIsoM with
MISO, Cu˙di˙, RSEM-EBSeq, and BitSeqVB in terms of the AUC (Area Under
Curve) of ROC (Receiver Operating Characteristic) curves on the synthetic data. The
ROC curves are computed based on di˙erent ranking criteria for the four methods.
DEIsoM uses the KL divergence; MISO uses both the average of Bayes factors of
all pairs of subjects (MISO-BF) and the average of KL divergences of posteriors of
isoform factions (MISO-KL); Cu˙di˙ uses a log-fold-change based p-value; RSEMEBSeq uses the PPDE (Posterior Probability of Di˙erential Expression); BitSeqVB
uses the PPLR (Probability of Positive Log Ratio). And we choose the “isoformcentric” mode for MISO. Also, PPLR is more sensitive to the upregulated DE isoforms
than the downregulated ones by defnition. Figure 3.4 (A) shows the ROC curves
RNASeqReadSimulator
is
available
at:
http://alumni.cs.ucr.edu/~liw/
rnaseqreadsimulator.html
3
Our simulation code is available at: https://github.com/hao-peng/DEIsoM/tree/master/
simulation
2
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for one of the 10 repeated experiments. Figure 3.3 (B) summarizes the means and
standard errors of the AUCs over 10 runs. They show that DEIsoM consistently
outperforms MISO-BF, MISO-KL, Cu˙di˙, and RSEM-EBSeq on the synthetic data
under our settings.
Third, we compare the CPU time of DEIsoM, Cu˙di˙, RSEM-EBSeq and BitSeqVB. The time we count is from the point we give the alignment fles as input to
the point that the programs generate the quantifcation results. We summarize it in
Supplementary Table 3.2 for one run of the simulated data and the real data which
will be discussed in Section 3.5. The numbers of hours used by the three algorithms
are comparable, where Cu˙di˙ is always the fastest in all methods. However, DEIsoM has better DE isoform identifcation and quantifcation performance than the
alternative methods, which is shown in both Section 3.4 and Section 3.5.

3.4.2

Comparison of VB and MCMC on synthetic data

To test whether the VB inference algorithm speeds up the computation over
MCMC sampling without loss of accuracy, we compare the ROC curves and running
time of the two implementations. We set the maximum iteration number as 1500
for both VB and MCMC. The burn-in time of MCMC is 150 iterations. Note that
the MCMC sampling here is not completely the same as MISO. MISO combines the
Metropolis-Hasting algorithm with a Gibbs sampler. We follow the same approach
to estimate ψ, but we iteratively sample α from its posterior distribution given a
non-informative prior which depends on all fve replicates. Details of our MCMC
sampling method are described in the Supplementary 3.8.1. The VB inference shows
an advantage over MCMC in both the ROC curve and computing time within the
limited number of iterations. Figure 3.4(B) shows the ROC curves for both implementations; VB inference achieves an AUC=0.9445 in 1.4 CPU hours, whereas the
MCMC method has AUC=0.8844 in 56 CPU hours. Although MCMC theoretically
can give samples from the exact target posterior distribution, it converges slowly on
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this dataset, which may cause inaccurate predictions and long running time. However, VB usually converges before the limit is reached under the same number of
maximum iterations. Therefore, the VB method achieves a faster speed and a higher
accuracy than the MCMC sampling.
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Fig. 3.3.: RNA-Seq simulation studies. (A) Means and standard errors of correlation
coeÿcients between the estimation and the ground truth in 10 replicates, using DEIsoM, MISO, RSEM, BitSeqVB and Cu˙di˙. (B) Means and standard errors of AUCs
of 10 repeated simulations for DEIsoM, MISO-KL, MISO-BF, Cu˙di˙, RSEM-EBSeq
and BitSeqVB.

3.4.3

Comparison of sensitivity of fve methods

To demonstrate the robustness of DEIsoM, we vary the parameter of Dirichlet
distribution α used for generating isoform fractions. When we increase α, the variance
of generated isoform fractions under two conditions becomes smaller, but the mean
remains the same. As a result, the diÿculty of distinguishing DE genes from nonDE genes increases. In this experiment, we set α = 1, 3 and 5 and keep the other
settings unchanged to simulate the data. We test all above fve methods on the
simulated reads to see whether they are sensitive to the change of α. Table 3.1 shows
that as α increases, the AUCs of all methods decrease, since the task becomes harder.
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Fig. 3.4.: RNA-Seq simulation studies. (A) ROC curve comparison of MISO, Cu˙di˙, RSEM-EBSeq, BitSeqVB and DEIsoM from one run of 10 repeated experiments.
For MISO we use two evaluation methods, MISO-KL and MISO-BF. MISO-KL denotes the average of KL divergences of the posteriors of isoform fractions. MISO-BF
denotes the average of Bayes factors. (B) ROC curve comparison of VB and MCMC
implementations of DEIsoM on the same dataset.

However, DEIsoM consistently outperforms the alternative methods throughout all
α settings.
α
MISO-BF
MISO-KL
Cu˙di˙
RSEM-EBSeq
BitSeqVB
DEIsoM

1
0.849
0.912
0.890
0.873
0.807
0.931

3
0.727
0.878
0.834
0.798
0.771
0.915

5
0.673
0.844
0.815
0.762
0.704
0.887

Table 3.1.: AUCs for MISO, Cu˙di˙, RSEM-EBSeq, BitSeqVB, and DEIsoM on
simulated data with di˙erent α.

3.4.4

Comparison of abundance estimation

To test the quantifcation performance of DEIsoM under a more realistic setting, we
simulate RNA-Seq reads using real data. Two RNA-Seq datasets of human stom-
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Dataset
scenario 1 (BitSeqVB)
scenario 2 (Cuffdiff)
scenario 3 (RSEM)
scenario 4 (DEIsoM)
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0.4
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DEIsoM

RSEM BitSeqVB Cuffdiff

Fig. 3.5.: Relative root mean squared errors of DEIsoM, RSEM, BitSeqVB and
Cu˙di˙ on four simulated datasets. Theta: estimated transcript fractional expression
compared with the ground truth for all the replicates. Theta-Group: mean estimated
transcript fractional expression of the whole group compared with the true group
mean. WGE-True: within-gene relative estimates compared with the ground truth.
WGE-Inter: inter-replicate consistency of within-gene relative estimates.

ach tissue were chosen from the ENCODE project4 . Following the same percedure
in Hensman et al. (2015), we estimate the abundance of 196, 317 transcripts using
four models, RSEM, Cu˙di˙, BitSeqVB and DEIsoM, as the ground truth for each
scenario. By feeding the ground truth to Spanki (Sturgill et al., 2013), we generate
about 10 millions paired-end reads for each of the fve replicates under each scenario. Four di˙erent evaluation criteria are used, see Supplementary 3.8.2: Theta,
Theta-Group, WGE-True and WGE-Inter. Theta measures the accuracy of transcript
fraction estimation for all the replicates; Theta-Group measures the accuracy of transcript fraction estimation for the whole group; WGE-True measures the accuracy of
within-gene relative fractional estimation; WGE-Inter measures the predictive conThe datasets from ENCODE project can be found at: https://www.encodeproject.org/
experiments/ENCSR853WOM/ and https://www.encodeproject.org/experiments/ENCSR752UNJ/
4
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sistency among all replicates. Figure 3.5 summarizes the relative root mean square
errors (RMSE) of DEIsoM, RSEM, BitSeqVB and Cu˙di˙ on four simulated datasets.
They show that the DEIsoM RMSEs in both Theta-Group and WGE-Inter are lower
than the other three methods, indicating that DEIsoM tends to give more consistent
and accurate estimates for the whole condition. This result is consistent with the one
in (Hensman et al., 2015). A similar result evaluated by the relative mean absolute
errors (MAE) is shown in Supplementary Figure 3.9.

3.5

Real data experiments and results
In this section, we test whether DEIsoM successfully identifes DE isoforms in real

data. We apply DEIsoM and alternative programs to a Hepatocellular Carcinoma
(HCC) RNA-seq dataset, and evaluate the predicted DE isoforms by PCA, read coverage visualization, and comparison to the biological literature. Aberrant alternative
splicing is known to be involved in HCC (Berasain et al., 2010), so DE isoforms should
be present.

3.5.1

Data pre-processing

RNA-seq data was collected from nine pairs of HCC tumors and their matched
adjacent normal tissues (Sung et al., 2012) (Kan et al., 2013). The mRNA of each
sample was extracted, amplifed and sequenced using the Illumina HiSeq 2000 platform. 150 base paired-end reads were generated and aligned to the hg19 human
reference genome using RUM (RNA-Seq Unifed Mapper) (Grant et al., 2011). The
aligned reads are used as input to three methods, Cu˙di˙, RSEM-EBSeq, and DEIsoM, for DE isoform detection. MISO is not included because it cannot perform a
group-wise analysis.
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3.5.2

PCA

Because there is no exact ground truth for the HCC real data, we evaluate the
quantifcation ability of each method by PCA plots. We frst choose 38 signifcantly
DE genes that are verifed by polymerase chain reaction (PCR) from the previous
publications (Dong et al., 2009; Wang et al., 2015; Huang et al., 2017; Wang et al.,
2017). For each gene, we sum up the Fragments Per Kilobase of transcript per
Million mapped reads (FPKM) of all the child isoforms as the gene expression. If
the gene/isoform expressions associated with the HCC are correctly estimated, these
gene/isoforms can be used as features to distinguish between the normal and tumor
samples in PCA plots. Figure 3.6 shows that DEIsoM and RSEM can linearly separate
tumor samples from their matched normal samples; BitSeqVB has one tumor sample
(9) very closed to the normal cluster; Cu˙di˙ misses three tumor samples (4,5,6) in
the normal cluster.

3.5.3

Read coverage visualization

To understand the expression patterns of the DE isoforms selected by DEIsoM, we
visualize the read coverage on the hg19 reference genome. Because it may be possible
to align a read to multiple isoforms, it is hard to determine the exact expression level
of each isoform from the read coverage visualization. But it is possible to tell the
change in isoform expression in some cases. A previous study successfully identifed
the genes with DE isoforms by testing the di˙erence in read coverage between two
conditions (Stegle et al., 2010). Following the same logic, we assume that if the read
coverage of a gene is similar in the two conditions, the isoforms of that gene will be
predicted as non-DE. Otherwise, they are more likely to be DE.
First, we examine the read coverage of IGF2, a gene identifed by DEIsoM as
having DE isoforms. IGF2 is the 2nd most DE gene identifed by DEIsoM. Eight isoforms of IGF2 have been observed according to the human transcriptome annotation.
Figure 3.7 (A, B) shows the read coverage of IGF2 in nine pairs of normal and tumor
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Fig. 3.6.: PCA plots for nine pairs of HCC samples and their matched normal
samples. Each sample is represented by a vector with 38 gene expressions. All
these 38 genes are PCR verifed DE genes in HCC. A, B, C, D are PCA plots using
the estimations from DEIsoM, BitSeqVB, RSEM and Cu˙di˙, respectively. Circle:
normal sample. Cross: tumor sample. Percentage: the proportion of variance of the
corresponding principle component.
samples. Note that the reads aligned to the last two exons (in the box) can only
contribute to isoform 4 (ENST00000300632). Figure 3.7(B) shows that the absolute
numbers of reads aligned to the last two exons in all tumor samples are much lower
than that in normal samples. Figure 3.7(C) is the same as Figure 3.7(B) but with an
automatically scaled y-axis. (C) shows that in eight of nine tumor samples (1T, 2T,
4T – 9T), the fractions of reads aligned to the last two exons are much lower in the
HCC samples than that in the normal samples. This indicates that IGF2 isoform 4
is down-regulated in HCC tumors. However, in the Cu˙di˙ results, this isoform has
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Fig. 3.7.: Read coverage of IGF2 – a top selection by DEIsoM. The data was normalized across replicates by scaling the total number of reads to that of 1N (replicate
1 under normal condition). (A) Read coverage patterns of nine normal samples with
y-axis scaled to 5000. (B) Read coverage patterns of nine matched tumor samples
with y-axis scaled to 5000. (C) is the same as (B) but uses an automatically scaled
y-axis. This illustrates that 1-5 and 8-9 tumor samples have very low read abundance
in the last two exons, and the low signals are not due to the imposition of a fxed
large y-axis scale. The exon positions of eight isoforms are listed under each panel.

73
a p-value of 0.039 with rank 95; in RSEM-EBSeq, the PPDE equal to 1 out of 1147
DE isoforms all with PPDE = 1. But if we further rank the RSEM-EBSeq result
by transcript real fold change (condition 1 over condition 2) as recommended, this
isoform ranks 671 out of 1147 DE isoforms.
Second, we show the read coverage of IGF2BP1, a gene identifed by Cu˙di˙ as
having DE isoforms. Isoform 1 (ENST00000290341) of IGF2BP1 is the 6th most DE
gene. Supplementary Figure 3.10 shows the read coverage of IGF2BP1 in normal
and tumor samples. Note that the reads aligned to the last exon only contribute
to isoform 1 (the box indicates the last exon). However, only four of nine tumor
samples show moderate di˙erential expression of isoform 1 (lower than 500), and the
expression level is near zero in all normal samples and fve of the tumor samples (1T –
4T, 8T). Cu˙di˙ evaluates DE level using the log-fold-change between the conditions.
This “fold” will be extremely large when the expression of one condition is near zero
and the other is slightly higher. However, due to the low count numbers in both
conditions, the confdence of calling this gene as having DE isoforms is low. Often,
an empirical value is set to avoid low signals (NOTEST or LOWDATA). On the
contrary, DEIsoM ranks IGF2BP1 as 244. Because both large sample variance and
low read coverage lead to relatively “fat” posterior distributions in both normal and
tumor conditions, which are close to the prior distribution. Thus, the KL divergence
between two posterior distributions is small and the isoforms are not identifed as DE.
Lastly, we visualize the fve least di˙erentially expressed isoforms identifed by
DEIsoM, showing that the low ranked isoforms have very similar read coverage patterns in both normal and tumor samples. Supplementary Figure 3.11 shows COX16
has a similar read coverage pattern among all samples in both normal and tumor
conditions. This is because a low KL divergence requires a high similarity between
two posterior distributions of isoform fraction.
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3.5.4

Biological relevance of predicted DE isoforms

To further understand the functions of DE isoforms selected by DEIsoM, we examine whether they are supported by HCC relevant literature. PubMed searches
were performed using the keywords “gene name + hepatocellular carcinoma”. Since
most current experimental work focuses on the expression levels of genes rather than
isoforms, we associate the DE isoforms identifed by DEIsoM, Cuÿdi˙ and RSEMEBSeq with their gene names. Also, we assume that if the expression of a gene
changes, it is very likely caused by a change of its isoforms. DE isoforms/genes are
then categorized into four groups (3, 2, 1, 0) according to their relevance to HCC.
“Category 3” refers to a gene whose function in HCC has been well studied and can
be used as a potential biomarker for prognosis or diagnosis. “Category 2” indicates
that di˙erential expression of a gene has been detected in vivo, but not used as a
biomarker. “Category 1” indicates a gene whose function has only been studied in
vitro but not in patient biopsies. “Category 0” indicates a gene for which we found
no HCC relevant literature.
60

Number of genes
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40

3 HCC biomarker
2 HCC tissue research
1 Cell line research

30
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Fig. 3.8.: HCC relevance of DE isoforms identifed by DEIsoM, BitSeqVB, Cu˙di˙
and RSEM-EBSeq. Relevance is defned as Category 3: HCC biomarkers, Category
2: DE genes verifed in HCC tissues, Category 1: DE genes verifed in HCC cell lines,
and Category 0: HCC non-related genes. We analyze both the top 10 and top 50
selections for all four methods.

75
First, we compare the number of genes that are HCC biomarkers (Category 3)
in the predictions by DEIsoM, BitSeqVB, RSEM-EBSeq and Cu˙di˙ (the frst four
columns in Figure 3.8). In the top 10 lists, more genes are identifed as HCC biomarkers by DEIsoM than BitSeqVB, RSEM-EBSeq or Cu˙di˙. Specifcally, 6/10 genes
identifed by DEIsoM (ASS1, TTR, IGF2, AHSG, GPC3, CRP) vs. 4/10 genes identifed by BitSeqVB (GPC3, AFP, IGF2BP3, UBE2C), 3/10 genes identifed by Cu˙di˙
(SKP2, C-FOS, SOCS2) and 3/10 genes identifed by RSEM-EBSeq (PEG10, TERT,
ACAN) and belong to Category 3.
Second, we have examined the six specifc HCC biomarkers status (ASS1,TTR,
IGF2, AHSG, GPC3, CRP) in the top 10 list of DEIsoM. Specifcally, ASS1 is detected to be down-regulated in HCC liver samples, which can be used to predict
metastatic relapse with a high sensitivity and specifcity (Tan et al., 2014); TTR is
down-regulated in HCC patient serum (Qiu et al., 2008); Seon-Hee Yim et al. (Yim
and Chung, 2010) state that both IGF2 and GPC3 are e˙ective biomarkers for HCC
– particularly, circulating IGF2 mRNA is positive in 34% of HCC patients and 100%
correlated with the extrahepatic metastasis; GPC3 has been reported to interact
with the Wnt signaling pathway to stimulate cell growth in HCC; GPC3 has also
been used combined with PEG10, MDK, SERPINI1, and QP-C as a classifer that
successfully distinguishes noncancerous hepatic tissues from HCCs (Yim and Chung,
2010); AHSG combined with two other HCC-associated antigens – KRT23 and FTL –
can be used to diagnose HCC with sensitivity up to 98.2% in joint tests and specifcity
up to 90.0% in serial tests. (Wang et al., 2009); CRP, an infammatory cytokine, is
highly expressed in HCC and its expression is correlated with tumor size, Child-Pugh
function and survival time (Jang et al., 2012).
Generally, DEIsoM ranks genes/isoforms highly associated with HCC on the top.
In the top 10 list (the frst four columns in Figure 3.8), 60% of genes identifed by
DEIsoM as having DE isoforms are experimentally proven HCC biomarkers (Category
3), and 90% are HCC biomarkers plus DE genes verifed in vivo (Category 3 + 2 ).
On the contrary, BitSeqVB, RSEM-EBSeq and Cu˙di˙ show a lower performance
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than DEIsoM – 30% to 40% of genes having DE isoforms that are experimentally
proved HCC biomarkers (Category 3), and 40% to 50% are HCC biomarkers plus DE
genes verifed in vivo (Category 3 + 2 ).
Even if we expand this search to top 50 lists (the ffth column in Figure 3.8 and
Supplementary Table 3.5), DEIsoM still identifes 18 genes (36%) as HCC biomarkers,
and 10 genes (20%) as DE genes verifed in vivo. However, BitSeqVB, RSEM-EBSeq
and Cu˙di˙ identify fewer literature proven DE genes than DEIsoM in the top 50
list (the last three columns in Figure 3.8 and Supplementary Table ??). BitSeqVB
identifes 16 genes (32%) as HCC biomarkers, 12 genes (24%) as DE genes in vivo;
RSEM-EBSeq identifes 12 genes (24%) as HCC biomarkers and 3 genes (6%) as DE
genes verifed in vivo; Cu˙di˙ identifes 11 genes (22%) as HCC biomarkers, 12 genes
(24%) as DE genes in vivo. Therefore, DEIsoM has a clear superior ability to select
DE genes that are supported by the published literature.
Moreover, the isoforms of four genes (FGFR2, survivin, ADAMTS13 and CD44)
identifed as DE by DEIsoM have been found to be up or down-regulated in HCC.
This provides additional support for DE genes identifed by DEIsoM. In the case of
FGFR2 (ranked 62 of 11950 genes), the FGFR2-IIIb isoform is down-regulated and
has been related to HCC aggressive growth, while the FGFR2-IIIc isoform is expressed
at the same level in normal and HCC tissues (Amann et al., 2010). All three isoforms
of survivin (ranked 120 of 11950 genes), survivin normal, survivin 2B and survivin
Delta Ex3 have been detected in well, moderately and poorly di˙erentiated HCC but
none of these are found in normal tissues (Takashima et al., 2005). RT-PCR results
are available for ADAMTS13 (ranked 201 of 11950 genes) showing di˙erences in the
expression of three known isoforms (WT and 1, 2) between normal liver tissue and
hepatoma cell lines (Shomron et al., 2010). For CD44 (ranked 607 of 11950 genes),
CD44-v6 is up-regulated in HCC, while CD44 standard form remains stable (Zhang
et al., 2010).
To more clearly understand the performance of di˙erent methods, we also examine the overlapping DE genes in the top 200 lists from the compared methods.
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Supplementary Table 3.3 shows the overlapping DE genes by feeding the FPKM of
all isoforms from each method to EBSeq. This tests the quantifcation similarity
between any two methods. According to the number of overlapping DE genes, the
quantifcation performance of RSEM and BitSeqVB are the most similar, followed
by RSEM and DEIsoM. Supplementary Table 3.4 shows the overlapping DE genes
using the DE evaluation methods of their own. This tests the performance of both
the quantifcation and DE identifcation. After changing the DE evaluation method,
the number of overlapping DE genes between RSEM and BitSeq decreases from 96
to 62, while this number between RSEM and DEIsoM decreases from 74 to 14, which
suggests that KL divergence performs di˙erently from PPDE or PPLR. PPDE and
PPLR are only sensitive to the absolute abundance change of an isoform, while KL
divergence is sensitive to the overall isoform fractional pattern change within a gene,
not limited to the absolute abundance change. This is useful in searching isoform
switching events in many cases.

3.6

Discussion
In contrast to the models that treat each biological replicate separately, DEIsoM

incorporates all biollogical replicates in one seamless framework. By capturing the
shared information across multiple biological replicates, DEIsoM achieves a higher
prediction accuracy and inter-replicate consistency than the alternative methods in
the simulation studies (Section 3.4.1, 3.4.3, 3.4.4). This shared information comes
from the intrinsic fact that all the replicates in one condition share the same underlying biological mechanism. As described in model construction (Section 3.3.1), we use
a Dirichlet prior to represent a base fraction–which is characterized by the hyperparameter α and learned from data—and then sample the instance-specifc fraction for
each replicate. The fractions for di˙erent replicates are not necessarily the same —
because we allow some within-condition variance — however, those fractions retain
underlying coherence since they are sampled from the same Dirichlet prior (or the
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base fraction). In addition, as the conjugate prior for the multinomial distribution,
the Dirichlet prior enables close-form, eÿcient updates in our VB inference, which
greatly benefts the computation. Furthermore, faster computing speed is gained
using the VB algorithm, instead of the MCMC sampling used in MISO, during the
inference step. The VB method converts a sampling problem to an optimization problem and speeds up the estimation (Section 3.4.2). DEIsoM is also promising in real
applications. On the HCC dataset, by PCA plotting, we fnd that the normal and
tumor samples can be linearly separated by the estimated expression levels of PCR
verifed DE genes, suggesting an accurate quantifcation of DE isoforms in DEIsoM.
Using read coverage visualization, we fnd that the DEIsoM KL divergence is capable
of identifying isoforms whose read coverage patterns change, and does not give false
positive results for isoforms with low read abundance in both conditions. This property is desirable in practice, since a low number of reads causes a large uncertainty
in estimation. In DEIsoM, the posterior distributions of both conditions are close
to the uniformly distributed prior if the read number is low, which reduces the KL
divergence between the two conditions. However, neither Cu˙di˙ nor RSEM-EBSeq
will automatically prune such isoforms (Section 3.6, 3.7). Moreover, a great number
of isoforms predicted to be DE by DEIsoM are supported by the biological literature,
providing encouraging results for real applications.
However, there are still some improvements that could be incorporated into DEIsoM. First, DEIsoM builds on the approach of MISO, which considers the quantifcation of isoforms gene by gene. In order to handle the reads multi-mapped to di˙erent
gene loci, we have also added a variant version of DEIsoM that simultaneously considers all transcript isoforms, rather than performing a gene by gene analysis. This
enhancement will allow the inclusion of multiply mapped reads into the analysis.
However, the KL divergence is not applicable to this version, since KL divergence
measures the isoform pattern change within a gene. Second, the KL divergence as a
DE evaluation method is not based on a hypothesis test, but rather on the di˙erence
of the posterior distributions of fractional isoform expression between two conditions,
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so it only provides a rank instead of p-values to infer “signifcantly” DE genes. However, KL divergence is sensitive to the overall isoform pattern change within a gene,
and more di˙erentiable for ranking isoforms/genes than p-values, which tend to give
the same rank to many genes. DEIsoM allows the estimated isoform levels to be
reported as FPKM, thereby allowing p-values to be calculated by many existing differential expression analysis methods. Lastly, DEIsoM assumes a known reference
genome/transcriptome and the uniform read distribution. The misannotation or the
non-uniformity of the read data may compromise the estimation accuracy in DEIsoM. We are considering including the novel isoform construction and the modeling
of non-uniformly distributed read data into our future versions.

3.7

Conclusion
We propose a hierarchical Bayesian model, DEIsoM, for detecting DE isoforms

using multiple biological replicates from two conditions. DEIsoM captures the information shared across replicates, and provides fast and accurate prediction compared
to alternative methods in simulations. On the HCC real dataset, the estimated expression levels of PCR verifed DE genes can be used as features to separate the tumor
samples from their matched normal samples in PCA plots; read coverage visualization
confrms that DEIsoM KL divergence is capable of identifying DE isoforms. DEIsoM
is relatively resistant, compared to alternative methods, to identifying isoforms with
low read abundance in both conditions as DE. Biological literature review suggests
that the DE isoforms selected by DEIsoM have high relevance to HCC.
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3.8

Supplementary materials

3.8.1

Model

Derivations for the variational Bayesian inference
First we compute a variational lower bound for the log model evidence:
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The (i, j)th element of the Hessian matrix is
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while σ(i, j) = 1 if and only if i = j, otherwise σ(i, j) = 0. To ensure α is always
positive during optimization, we let γ = log(α) and optimize γ instead. Taking the
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Model inference with MCMC sampling
We use the Markov chain Monte Carlo (MCMC) inference method to compare
with our proposed Variational Bayesian (VB) inference method. Similarly to MISO,
we use a combination of Metropolis-Hastings (MH) algorithm and a Gibbs sampling
algorithm. Within a replicate, the sampling steps are exactly the same as MISO.
To sample the target posterior distribution, p(ψ (m) |R, λ), we use a softmax-normal
distribution as the purposed the distribution for the MH algorithm. To sample the
target posterior distribution, p(Z|R, λ), we use the usual Gibbs steps for DirichletMultinomial models. Di˙erent from MISO, we assume a non-informative prior for
α, such that p(α) is a constant. We use an additional MH sampling step to sample
α from its posterior distributions given the samples of {ψ (m) }M , where we use a
log-normal distribution as the proposal distribution. The sampling scheme follows:

(m)

βl

)

83
(m)

(m)

1. Initialize α0 , and for m = 1..M initialize µ0 , ψ0

(m)

and Z0

2. For t = 1..[max number of iterations]:
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where q(·) is the proposed softmax-normal distribution.
iii. For n = 1..N (m) :
A. Compute the conditional posterior of assigning a read for every
isoform 1 ≤ k ≤ K:
(m)

(m)

θi = p(Zn,k = 1|ψt+1 , Rn(m) , λn(m) )
B. Sample an assignment for this read:
(m)

Zn,t+1 ∼ Multinomial(1, [θ1 , ...θK ])
(b) Propose αt+1 as:
˜
αt+1 ∼ ln N (ln(αt ), Σ)
where ln N (·) denotes the log-normal distribution.
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(c) Accept αt+1 with probability:

P̃accept = min
(1)



p(ψt+1 , αt+1 )q(αt |αt+1 )
,1
p(ψt+1 , αt )q(αt+1 |αt )

(M )

where ψt+1 includes ψt+1 ..ψt+1 and q(·) is the proposed log-normal distribution.

3.8.2

Simulated data

Evaluation measures
The following evaluation measures with root mean square errors are used:
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for each replicate using negative binomial process.
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Fig. 3.9.: Relative mean absolute errors (MAEs) of DEIsoM, RSEM, BitSeq and
Cu˙di˙ on four simulated datasets. Theta: estimated relative transcript expression
compared with the ground truth for replicates. Theta-Group: mean estimated relative
transcript expression of replicates compared with the true group means. WGE-True:
within gene estimates compared with the ground truth. WGE-Inter: inter-replicate
consistency of within gene estimates.

Table 3.2.: A comparison between the total CPU times for methods evaluated on
synthetic data and real data. We include the user time and system time in computing
the total CPU time.
Simulated data
Real HCC data

DEIsoM
1.4h
137h

Cu˙di˙
1.1h
56.9h

RSEM-EBSeq
1.5h
353h

BitSeq
3.2h
95.8h
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Real data
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Fig. 3.10.: The read coverage visualization of the top DE isoform selected by Cu˙di˙.
The isoform 1 (blue box) of IGF2BP1 has been identifed as the 6th most DE isoform
by Cu˙di˙. The left panels show the read coverage patterns of nine normal samples,
whereas the right panels show the read coverage of nine matched tumor samples.

Table 3.3.: The number of overlapped genes in the top selected DE genes between
methods. All methods use the same evaluation method to rank the gene. The FPKM
have been computed by DEIsoM, Cu˙di˙, RSEM and BitSeqVB frst. Then EBSeq
is used to rank the DE genes.
# of selected genes
BitSeq and RSEM-EBSeq
RSEM-EBSeq and DEIsoM
RSEM-EBSeq and Cu˙di˙
BitSeq and DEIsoM
BitSeq and Cu˙di˙
Cu˙di˙ and DEIsoM

10
1
0
1
1
1
2

20
1
2
4
2
3
3

50
14
12
11
10
9
6

100
39
33
34
34
24
23

200
96
74
73
71
62
51
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Fig. 3.11.: The read coverage visualization of the bottom selection by DEIsoM. The
isoforms of COX16 are selected as non-DE. The left panels show the read coverage
patterns of nine normal samples, whereas the right panels show nine matched tumor
samples. It illustrates that the read coverage patterns are very similar between two
conditions.

Table 3.4.: The number of overlapped genes in the top selected DE genes between
methods. Di˙erent methods use di˙erent DE evaluations to rank the gene. Cu˙di˙
uses log-fold-change based p-values; RSEM uses PPDE and further real fold change
estimated by EBSeq; BitSeqVB uses PPLR; DEIsoM uses KL divergence.
# of selected genes
BitSeq and RSEM-EBSeq
RSEM-EBSeq and Cu˙di˙
RSEM-EBSeq and DEIsoM
BitSeq and Cu˙di˙
BitSeq and DEIsoM
Cu˙di˙ and DEIsoM

10
2
0
0
0
1
0

20
5
0
0
0
2
0

50
11
1
1
0
2
0

100
26
3
4
2
6
1

200
62
23
14
13
11
3
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Table 3.5.: Biological relevance of the top 50 DE genes selected by DEIsoM on HCC
data and the corresponding references (Date: by 2016-11-12).
Rank
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

Gene ID
ENSG00000130707
ENSG00000118271
ENSG00000167244
ENSG00000145192
ENSG00000011465
ENSG00000243649
ENSG00000188257
ENSG00000250722
ENSG00000147257
ENSG00000132693
ENSG00000019582
ENSG00000138115
ENSG00000166710
ENSG00000055957
ENSG00000081051
ENSG00000151655
ENSG00000159403
ENSG00000100197
ENSG00000244255
ENSG00000169439
ENSG00000167711
ENSG00000185813
ENSG00000166741
ENSG00000160862
ENSG00000167996
ENSG00000122786
ENSG00000142541
ENSG00000117601
ENSG00000109971
ENSG00000185624
ENSG00000142192
ENSG00000160868
ENSG00000204628
ENSG00000008394
ENSG00000197111
ENSG00000148672
ENSG00000136011
ENSG00000116171
ENSG00000110492
ENSG00000213494
ENSG00000166278
ENSG00000114867
ENSG00000142748
ENSG00000003436
ENSG00000198363
ENSG00000116882
ENSG00000197746
ENSG00000198848
ENSG00000138674
ENSG00000127831

Symbol
ASS1
TTR
IGF2
AHSG
DCN
CFB
PLA2G2A
SEPP1
GPC3
CRP
CD74
CYP2C8
B2M
ITIH1
AFP
ITIH2
C1R
CYP2D6
SDC2
SERPINF2
PCYT2
NNMT
AZGP1
FTH1
CALD1
RPL13A
SERPINC1
HSP70
P4HB
APP
CYP3A4
GNB2L1
MGST1
PCBP2
GLUD1
STAB2
SCP2
MDK
CCL14
C2
EIF4G1
FCN3
TFPI
ASPH
HAO2
PSAP
CES1
SEC31A
VIL1

Level
3
3
3
3
2
2
0
2
3
3
0
0
2
0
3
0
0
2
0
0
2
0
3
3
0
0
2
3
3
0
1
3
2
0
3
0
2
0
3
0
0
0
2
0
3
3
0
3
0
3

Reference
https://www.ncbi.nlm.nih.gov/pubmed/24946162
https://www.ncbi.nlm.nih.gov/pubmed/17828420
https://www.ncbi.nlm.nih.gov/pubmed/21769080
https://www.ncbi.nlm.nih.gov/pubmed/19304375
https://www.ncbi.nlm.nih.gov/pubmed/12521301
https://www.ncbi.nlm.nih.gov/pubmed/24195504
https://www.ncbi.nlm.nih.gov/pubmed/19304375
https://www.ncbi.nlm.nih.gov/pubmed/22706665
https://www.ncbi.nlm.nih.gov/pubmed/1337988
https://www.ncbi.nlm.nih.gov/pubmed/10879242
https://www.ncbi.nlm.nih.gov/pubmed/22620007
https://www.ncbi.nlm.nih.gov/pubmed/16048566
https://www.ncbi.nlm.nih.gov/pubmed/16980951
https://www.ncbi.nlm.nih.gov/pubmed/19216803
https://www.ncbi.nlm.nih.gov/pubmed/22625427
https://www.ncbi.nlm.nih.gov/pubmed/12029631
https://www.ncbi.nlm.nih.gov/pubmed/16820872
https://www.ncbi.nlm.nih.gov/pubmed/16820872
https://www.ncbi.nlm.nih.gov/pubmed/14673798
https://www.ncbi.nlm.nih.gov/pubmed/9243801
https://www.ncbi.nlm.nih.gov/pubmed/23891548
https://www.ncbi.nlm.nih.gov/pubmed/16820872
https://www.ncbi.nlm.nih.gov/pubmed/27748915
https://www.ncbi.nlm.nih.gov/pubmed/23870052
https://www.ncbi.nlm.nih.gov/pubmed/17317821
https://www.ncbi.nlm.nih.gov/pubmed/17006932
https://www.ncbi.nlm.nih.gov/pubmed/22245894
https://www.ncbi.nlm.nih.gov/pubmed/26658681
https://www.ncbi.nlm.nih.gov/pubmed/19658107
https://www.ncbi.nlm.nih.gov/pubmed/22530999
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Table 3.6.: Biological relevance of the genes of the top 50 DE isoforms selected
by RSEM-EBSeq on HCC data and the corresponding references (Date: by 2016-1112).(∗ : Clone-based (Vega))
Rank
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

Gene ID
ENSG00000242265
ENSG00000187243
ENSG00000130829
ENSG00000164362
ENSG00000206557
ENSG00000225546
ENSG00000157766
ENSG00000225210
ENSG00000159217
ENSG00000238107
ENSG00000139219
ENSG00000185686
ENSG00000231196
ENSG00000223572
ENSG00000096088
ENSG00000126752
ENSG00000254233
ENSG00000253293
ENSG00000214814
ENSG00000136231
ENSG00000233539
ENSG00000110347
ENSG00000228651
ENSG00000181617
ENSG00000081051
ENSG00000043355
ENSG00000106031
ENSG00000107984
ENSG00000133063
ENSG00000147485
ENSG00000179083
ENSG00000264424
ENSG00000172016
ENSG00000226674
ENSG00000074211
ENSG00000086548
ENSG00000154277
ENSG00000178999
ENSG00000168955
ENSG00000183837
ENSG00000163993
ENSG00000168243
ENSG00000112818
ENSG00000236849
ENSG00000171243
ENSG00000198074
ENSG00000204832
ENSG00000251049
ENSG00000123496
ENSG00000229183

Symbol
PEG10
MAGED4B
DUSP9
TERT
TRIM71
LVCAT5
ACAN
AL589743.1∗
IGF2BP1
RP11-495P10.5∗
COL2A1
PRAME
RP11-495P10.8∗
CKMT1A
PGC
SSX1
LVCAT8
HOXA10
FER1L6
IGF2BP3
LOC730338
MMP12
RP11-556E13.1∗
FDCSP
AFP
ZIC2
HOXA13
DKK1
CHIT1
PXDNL
FAM133A
MYH4
REG3A
TEX41
PPP2R2C
CEACAM6
UCHL1
AURKB
TM4SF20
PNMA3
S100P
GNG4
MEP1A
LINC01474
SOSTDC1
AKR1B10
ST8SIA6-AS1
RP11-685F15.1∗
IL13RA2
PGA4

Level
3
0
0
3
0
0
3
0
2
0
1
0
0
0
0
1
0
1
0
3
0
3
0
0
3
1
3
3
0
0
0
0
2
0
0
0
2
3
0
0
3
0
3
0
0
3
0
0
0
0

Reference
https://www.ncbi.nlm.nih.gov/pubmed/24369324
https://www.ncbi.nlm.nih.gov/pubmed/26099527
https://www.ncbi.nlm.nih.gov/pubmed/22912547
https://www.ncbi.nlm.nih.gov/pubmed/24395596
https://www.ncbi.nlm.nih.gov/pubmed/21731504
https://www.ncbi.nlm.nih.gov/pubmed/24798046
https://www.ncbi.nlm.nih.gov/pubmed/25120782
https://www.ncbi.nlm.nih.gov/pubmed/18802962
https://www.ncbi.nlm.nih.gov/pubmed/21683576
https://www.ncbi.nlm.nih.gov/pubmed/22620007
https://www.ncbi.nlm.nih.gov/pubmed/26426078
https://www.ncbi.nlm.nih.gov/pubmed/25341685
https://www.ncbi.nlm.nih.gov/pubmed/27458854
https://www.ncbi.nlm.nih.gov/pubmed/16314847
https://www.ncbi.nlm.nih.gov/pubmed/18666234
https://www.ncbi.nlm.nih.gov/pubmed/20799978
https://www.ncbi.nlm.nih.gov/pubmed/23785431
https://www.ncbi.nlm.nih.gov/pubmed/26660154
https://www.ncbi.nlm.nih.gov/pubmed/27672277
-
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Table 3.7.: Biological relevance of the gene of the top 50 DE isoforms selected by
Cu˙di˙ on HCC data and the corresponding references (Date: by 2016-11-12).(∗ :
Clone-based (Vega))
Rank
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

Gene ID
ENSG00000145604
ENSG00000170345
ENSG00000171848
ENSG00000232001
ENSG00000116761
ENSG00000197408
ENSG00000130635
ENSG00000120833
ENSG00000238106
ENSG00000236786
ENSG00000171408
ENSG00000121691
ENSG00000174992
ENSG00000183748
ENSG00000216649
ENSG00000167780
ENSG00000090889
ENSG00000263585
ENSG00000205362
ENSG00000219607
ENSG00000249842
ENSG00000226164
ENSG00000260886
ENSG00000128266
ENSG00000162769
ENSG00000184374
ENSG00000232164
ENSG00000072080
ENSG00000092621
ENSG00000116017
ENSG00000156510
ENSG00000162409
ENSG00000136040
ENSG00000157131
ENSG00000143842
ENSG00000230328
ENSG00000224902
ENSG00000099860
ENSG00000172073
ENSG00000104549
ENSG00000169174
ENSG00000130222
ENSG00000108448
ENSG00000126231
ENSG00000006074
ENSG00000143369
ENSG00000236362
ENSG00000126752
ENSG00000235494
ENSG00000130427

Symbol
SKP2
C-FOS
R2
AC108868.6∗
CTH
CYP2B6
COL5A1
SOCS2
TSPY15P
PDE7B
CAT
ZG16
LOC101928757
GAGE12E
ACAT2
KIF4A
RP11-498C9.13∗
MT1A
PPP1R3G
CTD-2331D11.4∗
FGFR3P6
TAT-AS1
GNAZ
FLVCR1
COLEC10
LOC729348
SPP2
PHGDH
ARID3A
HKDC1
PRKAA2
PLXNC1
C8A
SOX13
RP11-35N6.6∗
GAGE12H
GADD45B
TEX37
SQLE
PCSK9
GADD45G
TRIM16L
PROZ
CCL18
ECM1
GAGE12F
SSX1
RP11-498P14.4∗
EPO

Level
3
3
0
0
0
2
0
3
0
0
0
3
2
0
0
2
2
0
3
0
0
0
0
2
2
0
0
0
1
2
3
2
0
3
2
0
0
3
0
2
3
2
0
2
1
3
0
1
0
3

Reference
https://www.ncbi.nlm.nih.gov/pubmed/27779207
https://www.ncbi.nlm.nih.gov/pubmed/22582734
https://www.ncbi.nlm.nih.gov/pubmed/25024626
https://www.ncbi.nlm.nih.gov/pubmed/23475171
https://www.ncbi.nlm.nih.gov/pubmed/21985599
https://www.ncbi.nlm.nih.gov/pubmed/17307141
https://www.ncbi.nlm.nih.gov/pubmed/24163426
https://www.ncbi.nlm.nih.gov/pubmed/25998931
https://www.ncbi.nlm.nih.gov/pubmed/16703398
https://www.ncbi.nlm.nih.gov/pubmed/16264227
https://www.ncbi.nlm.nih.gov/pubmed/27387388
https://www.ncbi.nlm.nih.gov/pubmed/25872475
https://www.ncbi.nlm.nih.gov/pubmed/27458175
https://www.ncbi.nlm.nih.gov/pubmed/27155152
https://www.ncbi.nlm.nih.gov/pubmed/27216817
https://www.ncbi.nlm.nih.gov/pubmed/26414287
https://www.ncbi.nlm.nih.gov/pubmed/24160375
https://www.ncbi.nlm.nih.gov/pubmed/12759252
https://www.ncbi.nlm.nih.gov/pubmed/25787749
https://www.ncbi.nlm.nih.gov/pubmed/26674961
https://www.ncbi.nlm.nih.gov/pubmed/23897841
https://www.ncbi.nlm.nih.gov/pubmed/22689435
https://www.ncbi.nlm.nih.gov/pubmed/26449829
https://www.ncbi.nlm.nih.gov/pubmed/27460906
https://www.ncbi.nlm.nih.gov/pubmed/24798046
https://www.ncbi.nlm.nih.gov/pubmed/26097591
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Table 3.8.: Biological relevance of the gene of the top 50 DE isoforms selected by
BitSeqVB-PPLR on HCC data and the corresponding references (Date: by 2016-1112).(∗ : Clone-based (Vega))
Rank
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

Gene ID
ENSG00000159217
ENSG00000260518
ENSG00000147257
ENSG00000158402
ENSG00000043355
ENSG00000081051
ENSG00000136231
ENSG00000206557
ENSG00000099953
ENSG00000175063
ENSG00000198074
ENSG00000143228
ENSG00000024526
ENSG00000164362
ENSG00000175329
ENSG00000112742
ENSG00000034063
ENSG00000074410
ENSG00000101057
ENSG00000130829
ENSG00000109805
ENSG00000085831
ENSG00000089685
ENSG00000125780
ENSG00000175793
ENSG00000123485
ENSG00000117650
ENSG00000113296
ENSG00000154545
ENSG00000011426
ENSG00000163808
ENSG00000111206
ENSG00000198758
ENSG00000142945
ENSG00000187243
ENSG00000165480
ENSG00000174371
ENSG00000185686
ENSG00000156970
ENSG00000228651
ENSG00000111665
ENSG00000169213
ENSG00000135451
ENSG00000066279
ENSG00000198203
ENSG00000176092
ENSG00000166851
ENSG00000169679
ENSG00000129173
ENSG00000072571

Symbol
IGF2BP1
BMS1P8
GPC3
CDC25C
ZIC2
AFP
IGF2BP3
TRIM71
MMP11
UBE2C
AKR1B10
NUF2
DEPDC1
TERT
ISX
TTK
UHRF1
CA12
MYBL2
DUSP9
NCAPG
TTC39A
BIRC5
TGM3
SFN
HJURP
NEK2
THBS4
MAGED
ANLN
KIF15
FOXM1
EPS8L3
KIF2C
MAGED4B
SKA3
EXO1
PRAME
BUB1B
RP11-556E13.1∗
CDCA3
RAB3B
TROAP
ASPM
SULT1C2
CRYBG2
PLK1
BUB1
E2F8
HMMR

Level
2
0
3
0
1
3
3
0
0
3
3
2
3
3
2
3
3
0
3
0
2
0
2
0
2
0
3
3
0
3
2
2
0
0
0
0
0
0
2
0
2
0
0
3
0
0
3
2
2
3

Reference
https://www.ncbi.nlm.nih.gov/pubmed/24395596
http://www.ncbi.nlm.nih.gov/pubmed/22706665
https://www.ncbi.nlm.nih.gov/pubmed/26426078
http://www.ncbi.nlm.nih.gov/pubmed/22620007
https://www.ncbi.nlm.nih.gov/pubmed/18802962
https://www.ncbi.nlm.nih.gov/pubmed/17354233
https://www.ncbi.nlm.nih.gov/pubmed/27672277
https://www.ncbi.nlm.nih.gov/pubmed/25374179
https://www.ncbi.nlm.nih.gov/pubmed/25605201
https://www.ncbi.nlm.nih.gov/pubmed/26099527
https://www.ncbi.nlm.nih.gov/pubmed/23221382
https://www.ncbi.nlm.nih.gov/pubmed/24859455
https://www.ncbi.nlm.nih.gov/pubmed/28060737
https://www.ncbi.nlm.nih.gov/pubmed/18624722
https://www.ncbi.nlm.nih.gov/pubmed/28238542
https://www.ncbi.nlm.nih.gov/pubmed/28238542
https://www.ncbi.nlm.nih.gov/pubmed/24859455
https://www.ncbi.nlm.nih.gov/pubmed/28101574
https://www.ncbi.nlm.nih.gov/pubmed/28177895
https://www.ncbi.nlm.nih.gov/pubmed/23717429
https://www.ncbi.nlm.nih.gov/pubmed/24859455
https://www.ncbi.nlm.nih.gov/pubmed/26289845
https://www.ncbi.nlm.nih.gov/pubmed/25753876
https://www.ncbi.nlm.nih.gov/pubmed/25236463
https://www.ncbi.nlm.nih.gov/pubmed/18676753
https://www.ncbi.nlm.nih.gov/pubmed/19725153
https://www.ncbi.nlm.nih.gov/pubmed/28238542
https://www.ncbi.nlm.nih.gov/pubmed/20068156
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4906898/
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4. CHAPTER 4. JOINT NETWORK AND NODE
SELECTION FOR PATHWAY-BASED GENOMIC DATA
ANALYSIS

This is a side project of my dissertation. The main tasks I did in this project were searching and
processing three cancer datasets, extracting and integrating KEGG pathway structures as matrices,
analyzing the biological results, and writing the section of “application to expression data”. Meanwhile, I learned the basic ideas of building a graphical Bayesian model and its inference method
from two other members in this team.
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4.1

Abstract

Motivation: By capturing various biochemical interactions, biological pathways provide insight into underlying biological processes. Given high-dimensional microarray
or RNA-sequencing data, a critical challenge is how to integrate them with rich information from pathway databases to jointly select relevant pathways and genes for
phenotype prediction or disease prognosis. Addressing this challenge can help us
deepen biological understanding of phenotypes and diseases from a systems perspective.
Results: In this article, we propose a novel sparse Bayesian model for joint network
and node selection. This model integrates information from networks (e.g. pathways)
and nodes (e.g. genes) by a hybrid of conditional and generative components. For the
conditional component, we propose a sparse prior based on graph Laplacian matrices,
each of which encodes between network nodes. For the generative component, we use
a spike and slab prior over network nodes. The integration of these two components,
coupled with eÿcient variational inference, enables the selection of networks as well
as correlated network nodes in the selected networks.
Simulation results demonstrate improved predictive performance and selection accuracy of our method over alternative methods. Based on three expression datasets for
cancer study and the KEGG pathway database, we selected relevant genes and pathways, many of which are supported by biological literature. In addition to pathway
analysis, our method is expected to have a wide range of applications in selecting
relevant groups of correlated high-dimensional biomarkers.
Availability: The code can be downloaded at :
http://www.cs.purdue.edu/homes/szhe/software.html
Contact: alanqi@purdue.edu
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4.2

Introduction
With the popularity of high-throughput biological data such as microarray and

RNA-sequencing data, many variable selection methods – such as lasso (Tibshirani,
1996) and elastic net (Zou and Hastie, 2005) – have been proposed and applied to select relevant genes for disease diagnosis or prognosis. Nevertheless, these approaches
ignore invaluable biological pathway information accumulated over decades of research; hence their selection results can be diÿcult to interpret biologically and their
predictive performance can be limited by a small sample size of expression profles. To
overcome these limitations, a promising direction is to integrate expression profles
with rich biological knowledge in pathway databases. Because pathways organize
genes into biologically functional groups and model their interactions that capture
correlation between genes, this information integration can improve not only the predictive performance but also interpretability of the selection results. Thus, a critical
need is to integrate pathway information with expression profles for joint selection
of pathways and genes associated with a phenotype or disease.
Despite their success in many applications, previous sparse learning methods are
limited by several factors for the integration of pathway information with expression
profles. For example, group lasso (Yuan and Lin, 2007) can be used to utilize memberships of genes in pathways via a l1/2 norm to select groups of genes, but they
ignore pathway structural information. An excellent work by Li and Li (2008) overcomes this limitation by incorporating pathway structures in a Laplacian matrix of a
global graph to guide the selection of relevant genes. In addition to graph Laplacians,
binary Markov random feld priors can be used to represent pathway information to
infuence gene selection (Wei and Li, 2007, 2008; Li and Zhang, 2010; Stingo and Vannucci, 2010). These network-regularized approaches do not explicitly select pathways.
However, not all pathways are relevant and pathway selection can yield insight into
underlying biological processes. A pioneering approach to joint pathway and gene
selection by Stingo et al. (2011) uses binary Markov random feld priors and couples
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gene and pathway selection by hard constraints – for example, if a gene is selected,
all the pathways it belongs to will be selected. However, this consistency constraint
might be too rigid from a biological perspective: an active gene for cancer progression does not necessarily imply that all the pathways it belongs to are active. Given
the Markov random feld priors and the nonlinear constraints, posterior distributions
are inferred by a Markov Chain Monte Carlo method (Stingo et al., 2011). But the
convergence of MCMC for high dimensional problems is known to take a long time.
To overcome these limitations, we propose a new sparse Bayesian approach, called
Network and NOde Selection (NaNOS), for joint pathway and gene selection. NaNOS
is a sparse hybrid Bayesian model that integrates conditional and generative components in a principled Bayesian framework Lasserre et al. (2006). For the conditional
component, we use a graph Laplacian matrix to encode information of each network
(e.g. a pathway) and incorporate it into a sparse prior to select individual networks.
For the generative component, we use a spike and slab prior to choose relevant nodes
(e.g. genes) in selected networks. For this hybrid model, we do not impose the hard
consistency constraints used by Stingo et al. (2011). Furthermore, the prior distribution of our model does not contain intractable partition functions. This enables us to
give a full Bayesian treatment over model parameters and develop an eÿcient variational inference algorithm to obtain approximate posterior distributions for Bayesian
estimation. As described in Section 4.4, our inference algorithm is designed to handle
both continuous and discrete outcomes.
Simulation results in Section 4.5 demonstrate superior performance of our method
over alternative methods for predicting continuous or binary responses, as well as comparable or improved performance for selecting relevant genes and pathways. Furthermore, on real expression data for large B cell lymphoma, pancreatic ductal adenocarcinoma, and colorectal cancer, our results yield meaningful biological interpretations
supported by biological literature.
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4.3

Model
In this section, we present the hybrid Bayesian model, NaNOS, for network

and node selection. First, let us start from the classical variable selection problem. Suppose we have N independent and identically distributed samples D =
{(x1 , t1 ), . . . , (xN , tN )}, where xi and ti are the explanatory variables and the response of the i-th sample, respectively. The explanatory variables can be various
biomarkers, such as gene expression levels or single-nucleotide polymorphisms. Following the tradition in variable selection, we normalize the values of each variable so
that its mean and standard deviation are zero and one, respectively. The response
can be certain phenotype or disease status. We aim to predict the response vector
t = [t1 , . . . , tN ]> based on the explanatory variables X = [x1 , . . . , xN ]T and to select
a small number of variables relevant for the prediction. Because the number of variables (e.g. genes) is often much bigger than the number of samples, the prediction
and selection tasks are statistically challenging.
To reduce the diÿculty of variable selection, we can use valuable information
from networks, each of which contains certain variables as nodes and represents their
interactions. For example, biological pathways cluster genes into functional groups,
revealing various gene interactions. Based M networks, we organize the explanatory
variables xi into M subvectors, each of which comprises the values of explanatory
variables in its corresponding network. If a variable (i.e. a gene) appears in multiple
networks (i.e. pathways), we duplicate its value in these networks. Note that networks
here are exchangeable with graphs; we can use them to represent not only biological
pathways but also linkage disequilibrium structures for genetic variation analysis.
Our model is a Bayesian hybrid of conditional and generative models based on a
general framework proposed by (Lasserre et al., 2006). The conditional component
selects individual networks via “discriminative" training; the generative component
chooses relevant nodes in the selected networks; and the two models are glued to-
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Fig. 4.1.: The graphical model representation of NaNOS.
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gether through a joint prior distribution, so that the selected networks can guide
node selection and, in return, the selected nodes can infuence network selection.
Specifcally, for the conditional model, we use a Gaussian data likelihood function
for the continuous response
p(t|X, w, τ ) =

N
Y

−1
).
N (ti |xT
i w, τ

(4.1)

i=1

where w are regression weights, each of which represents the contribution of the
corresponding node to the response, and τ is the precision parameter. For the unknown variance τ , we assign an uninformative di˙use Gamma prior, Gam(τ |g, h) with
g = h = 10−6 .
For the binary response, we use a logistic likelihood
YN
ti
1−ti
T
p(t|X, w) =
σ(xT
,
i w) [1 − σ(xi w)]
i=1

(4.2)

where ti ∈ {0, 1}, w are classifer weights, and σ(·) is the logistic function (i.e. σ(y) =
(1 + exp(−y))−1 ). Based on the M networks, we partition w into M groups, so that
w = [w1 , . . . , wM ]> where wk are the weights for the explanatory variables in the
k-th network.
To incorporate the topological information of a network, we use its normalized
Laplacian matrix representation. Specifcally, given an adjacent matrix Gk that represents the edges (i.e. interactions) between nodes in the k-th network, the normalized
Laplacian matrix Lk is defned as
⎧
⎪
⎪
1
⎪
⎪
⎪
⎨
Lk (i, j) = − √ 1
deg(i)deg(j)
⎪
⎪
⎪
⎪
⎪
⎩0
where deg(i) =

P

j

i = j and deg(i) 6= 0
i=
6 j and Gk (i, j) 6= 0
otherwise

Gk (i, j) is the degree of the i-th node in the k-th network.
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Based on the graph Laplacian matrices, we design the following mixture prior over
wk to select relevant networks:
αk
1−αk
p(wk |αk )=N (wk |0, s1 L−1
k ) N (wk |0, s2 Ik )

(4.3)

where αk is a binary variable indicating whether the k-th network is selected, s1 > s2 ,
s2 ≈ 0, and Ik is an identity matrix. We set the hyperparameters s1 , and s2 based on
cross-validation in our experiments. To make sure Lk is strictly positive-defnite, we
add a diagonal matrix 10−6 Ik to Lk . In (4.3), Lk captures the correlation information
between nodes in the k-th network. Note that if we replace Lk by Ik in the slab
component, the prior (4.3) becomes a simple generalization of the classical spike and
slab prior (George and McCulloch, 1997) for group selection. When αk = 1, the
k-th network is selected and the elements of wk are encouraged to be similar to each
other due to the Laplacian matrix Lk ; when αk = 0, because s2 is close to zero,
the corresponding Gaussian prior prunes wk . We use a Bernoulli prior distribution
to refect the uncertainty in αk , p(αk ) = (uk )αk (1 − uk )1−αk where uk ∈ [0, 1] is the
selection probability. Without any prior preference over selecting or pruning the k-th
network, we assign a uniform prior over uk : p(uk ) = 1 (i.e. p(uk ) = Beta(uk ; a, b)
where a = b = 1).
To identify relevant nodes, we introduce a latent vector w̃k in the generative model
for each network k, which is tightly linked to wk as explained later. We use a spike
and slab prior:
p(w̃k |βk ) =

pk
Y

N (w̃kj |0, r1 )βkj N (w̃kj |0, r2 )1−βkj

j=1
pk

=

Y

N (0|w̃kj , r1 )βkj N (0|w̃kj , r2 )1−βkj

j=1

= p(0|w̃k , βk )

(4.4)
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where pk is the number of nodes in the k-th network, r2 ≈ 0, and βkj is a binary
variable indicating whether to select the j-th node in the k-th network. We give
βkj a Bernoulli prior, p(βkj ) = (vkj )βkj (1 − vkj )1−βkj , and a uniform prior over vkj :
p(vkj ) = 1 (i.e., p(vkj ) = Beta(vkj |c, d) where c = d = 1). As shown above, the spike
and slab prior p(w̃k |βk ) has the same form as p(0|w̃k , βk ), which can be viewed as a
generative model – in other words, the observation 0 is sampled from w̃k . This view
enables us to combine the sparse conditional model for network selection with the
sparse generative model for node selection via a principled hybrid Bayesian model.
Specifcally, to link the conditional and generative models together, we introduce
a prior on w̃k :
p(w̃k |wk ) = N (w̃k |wk , λI)

(4.5)

where the variance λ controls how similar w̃k and wk are in our joint model. For
simplicity, we set λ = 0 so that p(w̃k |wk ) = δ(w̃k − wk ) where δ(f ) = 1 if f = 0 and
δ(f ) = 0 otherwise. The graphical model representation of the joint model is given
in Figure 4.1.
The network and node selections are consistent with each other in a probabilistic
sense. If a network is pruned, all its node are removed. Because wk = w̃k is enforced
by the prior δ(w̃k − wk ), when αk = 0, wk = 0 implies w̃k = 0. As a result, the spike
component in (4.4) will be selected for all the nodes in the k-th network (i.e., βkj = 0
for j = 1, . . . , pk ) with a higher probability than the slab component. On the other
hand, it is easy to see that, if one or multiple nodes in a network are selected, then
this network will be selected too. Note that, if a node appears in multiple networks
and is selected, our model will not force all the networks that contain this node to
be chosen. The reason is that we duplicate the value of this node in the networks
and treat their corresponding regression or classifcation weights as separate model
parameters.
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4.4

Algorithm
In this section, we present the variational Bayesian algorithm for model estima-

tion. Specifcally, we develop the variational updates to eÿciently approximate the
posterior distribution of weights w, the network-selection indicators α, the nodeselection indicators β, the network- and node-selection probabilities u and v, and the
precision parameter τ for regression. Based on the posteriors of α and β, we can
decide which networks and nodes are selected.
For regression, based on the model specifcation in Section 4.3, the posterior distribution of our model is
p(w, w̃, α, β, u, v, τ |t, X)
1
= N (t|Xw, τ −1 I)Gamma(τ )·
Z
Y
p(wk |αk )p(w̃k |wk )p(0|w̃k , βk )Bern(αk |uk )Beta(uk )·
k

Y

Bern(βkj |vkj )Beta(vkj )

(4.6)

j

where p(wk |αk ) and p(0|w̃k , βk ) are defned in (4.3) and (4.4), p(w̃k |wk ) = δ(w̃k −
wk ), and Z is the normalization constant. For classifcation, the posterior distribution
is similar to (4.6), except that we replace the Gaussian likelihood (4.1) by the logistic
function (4.2) and remove the precision parameter τ and its prior for regression in
(4.6).
Classical Markov chain Monte Carlo methods can be applied to approximate the
posterior distribution. However, given the high dimensionality of the parameters (e.g.,
w and α), it would take a long time for a sampler to converge. In practice it is even
diÿcult to judge the sampler’s convergence. Thus, we resort to a computationally
eÿcient variational approximation to (4.6).
Specifcally, we approximate the exact posterior distribution in (4.6) by a factorized distribution: Q(θ) = Q(w)Q(α)Q(β)
Q(u)Q(v)Q(τ ), where θ denotes all the latent variables. Note that, for classifcation,
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we do not have Qτ (τ ). Since we set p(w̃|w) = δ(w̃ − w), we do not need a separate
distribution Q(w̃). To solve Q(θ), we minimize the Kullback-Leibler (KL) divergence
between the exact and approximate posterior distributions of θ:
Z
KL(Q(θ)||p(θ|t, X)) =

Q(θ) ln

Q(θ)
dθ.
p(θ|t, X)

(4.7)

Applying coordinate descent for the minimization of (4.7), we obtain eÿcient updates for the variational distributions as described in the following sections. The
updates are iterative: we update one of the variational distributions at a time while
having all the other variational distributions fxed, and iterate these updates until
convergence. Since these updates monotonically decrease the value of the KL divergence (4.7), which is lower bounded by zero, they are guaranteed to converge in terms
of the KL value (Bishop, 2006).

4.4.1

Regression

The variational distributions for regression have the following forms:
Q(w) = N (w|m, Σ)
Y
Q(α) =
γk αk (1 − γk )1−αk
k
Y Y
Q(β) =
(ηkj )βkj (1 − ηkj )1−βkj
k
j
Y
Q(u) ∝
(uk )ãk −1 (1 − uk )b̃k −1
k
Y Y
˜
Q(v) ∝
(vkj )c˜kj −1 (1 − vkj )dkj −1
k

j

˜
Q(τ ) = Γ(τ |g,
˜ h).

(4.8)
(4.9)
(4.10)
(4.11)
(4.12)
(4.13)
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Their parameters are iteratively updated as follows:
Σ = (A + hτ iXT X)−1
ãk

= γk + a

m = hτ iΣXT t

(4.14)

b̃k = 1 − γk + b

(4.15)

d˜kj = 1 − ηkj + d
pk s1
γk = 1/(1 + exp(hln(1 − uk )i − hln uk i +
ln
2
s2
1
1
1
1
− ln |Lk | + tr(hwk wk T i( Lk − Ik ))
s2
2
2
s1
ηkj = 1/(1 + exp(hln(1 − vkj )i − hln vkj i
1 r1 1
1
1
+ ln + h(wkj )2 i( − )))
r1 r2
2 r2 2
X
T
˜ = h + 1 tT t − mT XT t + 1
h
xT
i hww ixi
i
2
2
N
g̃ = g +
2
1
where A = s1 diag({γk Lk }k ) + s12 diag({(1 − γk )Ik }k ) + r11 diag(η) +
c̃kj

(4.16)

= ηkj + c

(4.17)

(4.18)
(4.19)
(4.20)
1
diag(1
r2

− η)

(note that diag({γk Lk }k ) is a block-diagonal matrix), h·i means expectation over
the corresponding variational distribution, and the required moments in the above
equations are
hwwT i = Σ + mmT
hln uk i = ψ(ãk ) − ψ(ẽk )

hln(1 − uk )i = ψ(b̃k ) − ψ(ẽk )

hln vkj i = ψ(c̃kj ) − ψ(f˜kj )

hln(1 − vkj )i = ψ(d˜kj ) − ψ(f˜kj )

where ψ(x) =

4.4.2

˜
hτ i = g/
˜ h

d
dx

ln Γ(x), ẽk = ãk + b̃k and f˜kj = c̃kj + d˜kj .

Classifcation

Compared to regression, the classifcation task is more challenging. Because of
the logistic function (4.2), we cannot directly solve the variational distribution Q(w).
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Therefore, we use a lower bound proposed by (Jaakkola and Jordan, 2000) to replace
the logistic function in the joint distribution:
�
1−t
σ(y)t 1 − σ(y)
 (2t − 1)y − ξ
�

≥ σ(ξ) exp
− f (ξ) (2t − 1)2 y 2 − ξ 2
2
where f (x) =

1
4ξ

(4.21)

tanh(ξ/2), and ξ is a variational parameter. Note that the equality

is achieved when ξ = (2t − 1)y. Since the logarithm of the lower bound (4.21) is
quadratic in y, it essentially converts the logistic function into a Gaussian form so
that the variational inference becomes tractable.
Combining the maximization of the lower bound (4.21) with the minimization of
the KL divergence (4.7), we obtain the variational updates for classifcation. They
are the same as those for the regression task, except for that Q(w) = N (w|m, Σ),
now we have
X
�
−1
1
m= ΣXT (2t − 1)
Σ= A+2
f (ξi )xi xT
i
i
2

(4.22)

where A is the same as in the regression.
In addition, maximization of the lower bound of the logistic function gives the
update for the variational parameter ξi :
T
ξi2 = xT
i hww ixi .

4.4.3

(4.23)

Computational cost

The computational cost of the proposed algorithm is dominated by (4.14) for
regression and (4.22) for classifcation. For both cases, it takes O(p3 ) for matrix
inversion to obtain Σ and O(N p + p2 ) to obtain m for each iteration. Thus, the total
cost is O(p3 + N p) and, for most applications where p > N , it simplifes to O(p3 ).

110

1

90

0.8
F1

PMSE

80

60
0.6

40

Data 1

0.5

Data 2

Regression: PMSE

Data 2

Regression: F1
1

20

0.75

15
F1

Error rate (%)

Data 1

0.5

10

5

0.25

Data 1

Data 2

Classifcation: Error rate

Data 1

Data 2

Classifcation: F1

Fig. 4.2.: Prediction errors and F1 scores for gene selection in Experiment 1. ENet,
S&S, and GLasso stand for elastic net, the spike and slab model, and group lasso,
respectively; and Data 1 and 2 indicate the frst and second data generation models.
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4.5

Experiments
In this section, we apply NaNOS to synthetic and real gene expression data to

select pathways (i.e., networks) and genes (i.e., nodes), and provide biological analysis of our results. We also compare NaNOS with alternative methods, including
lasso Tibshirani (1996), elastic net Zou and Hastie (2005), group lasso Yuan and Lin
(2007); Jacob et al. (2009), the network-constrained regularization approach (Li and
Li (2008), henceforth “LL"), and the sparse Bayesian model with the classical spike
and slab prior (George and McCulloch, 1997). For lasso and elastic net, we used the
Glmnet software package 1 . For group lasso, we treat each pathway as a group. To
handle genes appearing in multiple pathways (i.e., groups), we frst duplicated their
expression levels for each group – as suggested by (Jacob et al., 2009) – and then
used the SLEP software package

2

for group lasso estimation. For the spike and slab

model, we implemented variational inference similar to our updates in Section 4.4.
Just as NaNOS, all these software packages use the Gaussian likelihood for regression
and the logistic likelihood for classifcation. We used the default confguration of
these software packages for the maximum number of iterations, initial values, and the
threshold for convergence. To tune regularization weights in lasso, group lasso and
the LL approach, we conducted thorough 10-fold cross validation (CV) on training
data (i.e., not using the test data) using a large computer cluster. The CV grids on
the free parameters are summarized here: for lasso, α = [0 : 0.01 : 1]; for elastic net,
α = [0 : 0.01 : 1] and β = [0 : 0.01 : 1]; for group lasso (both regression and logistic
regression), α = [0 : 0.01 : 1]; and for the LL approach, λ1 = [1 : 25 : 300] and
λ2 = [1 : 25 : 300] (we also did a second-level CV after we pruned the range of λ1 and
λ2 values based on the frst-level CV). Finally, for NaNOS, the cross-validation grids
are s1 = r1 = [0.1, 1, 3] and s2 = r2 = [10−3 , 10−4 , 10−5 , 10−6 ].
On the synthetic data for which we knew the true relevant pathways, we also
compared NaNOS with the popular tool for gene set enrichment analysis (GSEA)
1
2

www-stat.stanford.edu/˜tibs/glmnet-matlab/
www.public.asu.edu/˜jye02/Software/SLEP/
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(Mootha et al., 2003; Subramanian et al., 2005). We treated each pathway as a set,
used GSEA’s default confguration, and applied its suggested criterion FDR < 25%
to discover enriched pathways. We then identifed all the genes in these enriched
pathways as target genes. Because GSEA cannot provide predictions on responses t,
we did not include it for comparison on the real data.

4.5.1

Simulation studies

We frst compare all the methods on synthetic data in the following three experiments.
Experiment 1. We followed the frst and second data generation models used by Li
and Li (2008). Specifcally, we simulated expression levels of 200 transcription factors
(TFs), each controlling 10 genes in a simple tree-structured regulatory network, and
assumed that 4 pathways – including all of their genes – have e˙ect on the response
t. We sampled the expression levels of each TF from a standard normal distribution,
xT F ∼ N (0, 1) and the expression level of each gene that this TF regulates from
N (0.7xT F , 0.51). This implies a correlation of 0.7 between the TF and its target
genes.
For the frst model with the continuous response, we designed a weight vector
for each pathway, ρ = [1, √110 , . . . , √110 ], corresponding to the TF and 10 genes it
regulates, and then sampled t as follows:
w

=

t =

[5ρ, −5ρ, 3ρ, −3ρ, 0> ]>
Xw + 

where  ∼ N (0, σe2 ) and 0 is a vector of all zeros.
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Fig. 4.4.: Prediction errors and F1 scores for gene selection in Experiment 3.

The second model is the same as the frst one, except that the genes regulated by
the same TF can have either positive or negative e˙ect on the response t. Specifcally,
we set
ρ

=

−1 −1 −1
1
1
[1, √ , √ , √ , √ , . . . , √ ].
10
10
10
10
10
|
{z
}
7

For the frst and second models, the noise variance was set to be σe2 = (Σj wj2 )/4 so
that the signal-to-noise ratio was 12.85 and 7.54, respectively.
For the binary response, we followed the same procedure as for the continuous
response to generate expression profles X and the parameters w. Then we sampled
t from (4.2).
For each of the settings, we simulated 100 samples for training and 100 samples for
test. We repeated the simulation 50 times. To evaluate the predictive performance,
we calculated the prediction mean-squared error (PMSE) for regression and the error
rate for classifcation. To examine the accuracy of gene and pathway selection, we
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also computed sensitivity and specifcity and summarized them in the F1 score, F1 =
2 (sensitivity × speciﬁcity)/(sensitivity + speciﬁcity). The bigger the F1 score, the
higher the selection accuracy.
1
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Regression: F1
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EXP1−D1−D2 EXP2−D1−D2
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Classifcation: F1

Fig. 4.5.: F1 scores for pathway selection. “EXP” stands for “Experiment” and “D”
stands for “Data model”.

All the results are summarized in Figure 4.2, in which the error bars represent
the standard errors. For all the settings, NaNOS gives smaller errors and higher
F1 scores for gene selection than the other methods, except that, for classifcation
of the samples from the second data model, NaNOS and group lasso obtain the
comparable F1 scores. All the improvements are signifcant under the two-sample
t-test (p < 0.05). We also show the accuracy of group lasso, GSEA and NaNOS for
pathway selection in Figure 4.5. Again, NaNOS achieves signifcantly higher selection
accuracy. Because the LL approach was developed for regression, we did not have its
classifcation results. While the LL approach uses the topological information of all
the pathways, they are merged together into a global network for regularization. In
contrast, using a sparse prior over individual pathways, NaNOS can explicitly select
pathways relevant to the response, guiding the gene selection. This may contribute
to its improved performance.
Experiment 2. For the second experiment, we did not require all genes in relevant
pathways to have e˙ect on the response. Specifcally, we simulated expression levels
of 100 transcription factors (TFs), each regulating 21 genes in a simple regulatory
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network. We sampled the expression levels of the TFs, the regulated genes, and their
response in the same way as in Experiment 1, except that we set
1
1
ρ = [1, √ , . . . , √ , 0, . . . , 0]
21
21 | {z }
|
{z
}
11
10

for the frst data generation model and
ρ

=

−1 −1 −1
1
1
[1, √ , √ , √ , √ , . . . , √ , 0, . . . , 0]
21
21
21
21
21 | {z }
|
{z
}
11

(4.24)

7

for the second data generation model. Note that the last eleven zero elements in ρ
indicate that the corresponding genes have no e˙ect on the response t, even in the
four relevant pathways.
The results for both the continuous and binary responses are summarized in Figures 4.3 and 4.5. For regression based on the frst data model, NaNOS and LL obtain
the comparable F1 scores; for all the other cases, NaNOS signifcantly outperforms
the alternative methods in terms of both prediction and selection accuracy (p < 0.05).
Experiment 3. Finally, we simulated the data as in Experiment 2, except that we
√
replaced 21 in the denominators in (4.24) with 21, to obtain a weaker regulatory
e˙ect of the TF. Again, as shown in Figures 4.4 and 4.5, NaNOS outperforms the
competing methods signifcantly.

4.5.2

Application to expression data

Now we demonstrate the proposed method by analyzing gene expression datasets
for the cancer studies of di˙use large B cell lymphoma (DLBCL) (Rosenwald et al.,
2002), colorectal cancer (CRC) (Ancona et al., 2006), and pancreatic ductal adenocarcinoma (PDAC) (Badea et al., 2008). We used the probeset-to-gene mapping provided in these studies. For the CRC and PDAC datasets in which multiple probes were mapped to the same genes, we took the average expression level of
these probes. We used the pathway information from the KEGG pathway database

117
20

PMSE

2.65

2.55

2.45

(a) Di˙use large B cell lymphoma

Error rate (%)

2.75

16

12

(b) Colorectal cancer

Error rate (%)

13.5

11

9

(c) Pancreatic ductal adenocarcinoma
Fig. 4.6.: Predictive performance on three gene expression studies of cancer.

(www.genome.jp/kegg/pathway.html) by mapping genes from the cancer studies
into the database, particularly in the categories of Environmental Information Processing, Cellular Processes and Organismal Systems.
Di˙use large B cell lymphoma. We used gene expression profles of 240 DLBCL
patients from an uncensored study in the Lymphoma and Leukemia Molecular Profling Project (Rosenwald et al., 2002). From 7399 probes, we found 752 genes and
46 pathways in the KEGG dataset. The median survival time of the patients is 2.8
years after diagnosis and chemotherapy. We used the logarithm of survival times of
patients as the response variable in our analysis.
We randomly split the dataset into 120 training and 120 test samples 100 times
and ran all the competing methods on each partition. The test performance is visualized in Figure 4.6.a. NaNOS signifcantly outperforms lasso, elastic net and group
lasso. Although the results of the LL approach can contain connected sub-networks,
these sub-networks do not necessarily correspond to (part of) a biological pathway.
For instance, they may consist of components from multiple overlapped pathways. In
contrast, NaNOS explicitly selects relevant pathways. Four pathways had the selec-
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tion posterior probabilities larger than 0.95 and they were consistently chosen in all
the 100 splits. Two of these pathways are discussed below.
First, NaNOS selected the antigen processing and presentation pathway. The part
of this pathway containing selected genes is visualized in Figure 4.7.a. A selected
regulator CIITA was shown to regulate two classes of antigens MHC I and II in
DLBCL (Cycon et al., 2009). The loss of MHC II on lymphoma cells – including the
selected HLA-DMB, -DQB1, -DMA, -DRA, -DRB1, -DPA1, -DPB1, and -DQA1 –
was shown to be related to poor prognosis and reduced survival in DLBCL patients
(Rosenwald et al., 2002). The selected MHC I (e.g., HLA-A,-B,-C,-G) was reported
to be absent from the cell surface, allowing the escape from immunosurveillance of
lymphoma (Amiot et al., 1998). And the selected Ii/CD74 and HLA-DRB were
proposed to be monoclonal antibody targets for DLBCL drug design (Dupire and
Coiÿer, 2010).
Second, NaNOS chose cell adhesion molecules (CAMs). Adhesive interactions
between lymphocytes and the extracellular matrix are essential for lymphocytes’ migration and homing. For example, the selected CD99 is known to be over-expressed in
DLBCL and correlated with survival times (Lee et al., 2011), and LFA-1 (ITGB2/ITGAL)
can bind to ICAM on the cell surface and further lead to the invasion of lymphoma
cells into hepatocytes (Terol et al., 1999).
Colorectal cancer. We applied our model to a colorectal cancer dataset (Ancona
et al., 2006). It contains gene expression profles from 22 normal and 25 tumor tissues.
We mapped 2455 genes from 22,283 probes into 67 KEGG pathways. The goal was to
predict whether a tissue has the colorectal cancer or not and select relevant pathways
and genes.
We randomly split the dataset into 23 training and 24 test samples 50 times and
ran all the methods on each partition. The test performance is visualized in Figure
4.6.b. Again, based on a two-sample t-test, NaNOS outperforms the alternatives
signifcantly (p < 0.05). Three out of the four pathways with the selection posterior
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probabilities larger than 0.95 are discussed below. They were selected 20, 50 and 50
times in the 50 splits.
First, NaNOS selected the cell cycle pathway. This selection is consistent with the
original result by Ancona et al. (2006). As shown in 4.7.b, NaNOS selected mitotic
spindle assembly related genes. Specifcally, Bub1 and Mad1 may regulate the checkpoint complex (MCC) containing Mad2, BubR1 and Bub3. The upregulated MCC
may in turn inhibit ability of APC/C to ubiquitinate securin and further lead to mitotic event extension in CRC (Menssen et al., 2007). NaNOS also chose cyclin/CDK
complexes, among which CycD/CDK4 overexpression is found in mouse colon tumor
and CDK1, CDK2, CycE are increased in human CRC Wang et al. (1998); Vermeulen
et al. (2003). NaNOS further identifed MCM (minichromosome maintenance) complex – MCM2 and MCM5 – which are biomarkers for the CRC stage identifcation
(Giaginis et al., 2009). Moreover, the selected TP53 and c-Myc are known to be
closely related to CRC (Menssen et al., 2007).
Second, NaNOS chose the intestinal immune network for IgA production. A
greatly increased level of IgA – as a result of long-term intestinal infammation – can
increase the chance of CRC (Rizzo et al., 2011) and serve as an e˙ective biomarker
for early diagnosis of CRC (Chalkias et al., 2011). Also, selected chemkines in this
pathway, such as CXCR4 and CXCL12, may contribute to CRC progression (Sakai
et al., 2012).
Third, NaNOS selected the cytokine-cytokine receptor interaction pathway as well
as several well-known CRC-related molecules in this pathway. For instance, CXCL13
is a biomarker for stage II CRC prognosis (Agesen et al., 2012); CXCL10 dramatically
increases with CRC progression (Toiyama et al., 2012); and IL10 secreted by CRC cells
can accelerate tumor proliferation and be used for the prognosis of CRC progression
(Toiyama et al., 2010).
Pancreatic ductal adenocarcinoma. This cancer dataset includes expression profles from 39 PDAC and 39 normal subjects (Badea et al., 2008). By mapping 2781
genes from 54677 probes into KEGG pathways, we obtained 67 pathways. Our goal
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was to predict whether a subject has the pancreatic cancer and select relevant pathways and genes. We randomly split the dataset into 39 training and 39 test samples
50 times and ran all the methods on each partition. The test performance is visualized in Figure 4.6.c. Based on a two-sample t-test, NaNOS signifcantly outperforms
lasso, elastic net and group lasso.
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the performance of NaNOS degrades smoothly, but still better than the competing
methods.

To investigate the sensitivity of NaNOS to the structural noise in the pathway
database, we randomly chose 20%, 50%, 80% and 100% edges in each pathway and
removed them. We tested NaNOS for each case and reported the average test error
rate in the new Figure 4.8. As expected, the error rate of NaNOS gradually increases
with more edges being removed because less topological information in pathways is
available. But NaNOS still consistently outperformed all the alternative methods
such as elastic net, the second best method on this dataset. This experiment demonstrates i) that, by exploiting subtle correlation information embedded in the pathway
topology, NaNOS can boost its modeling power and predictive performance, and ii)
that NaNOS is robust to small perturbation in pathway topology.
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We also examined the impact of the important prior distributions on pathway
and gene selection probabilities uk and vkj . As described in Section 4.3, we used
the uniform priors (i.e., the Beta(1,1) prior) over uk and vkj , indicating no prior
preference over selecting a pathway or gene or not. The average test error based on
the uninformative priors is 9.15 ± 0.5, as visualized in Figure 4.6.c. If we change
the prior to a very informative one Beta(1,10) (mean 0.09 and standard deviation
0.083) that strongly prefers sparsity, then the average test error increases slightly to
10.0±0.4. This minor increase in error may stem from the over-sparifcation caused by
the sparsity prior that are over-confdent (suggested by a small variance). Now if we
use another informative prior Beta(10,1) (mean 0.91 and standard deviation 0.083)
that strongly prefers dense – instead of sparse – estimation, then the average test
error increases to 11.2 ± 0.5. This relatively larger error increase is exactly what we
expected because now the wrong dense prior aims to select most pathways and genes.
What is important is that, no matter which of these two informative priors we chose,
NaNOS consistently outperformed lasso and group lasso in 4.6.c. Between these two
extreme cases, if we use an uninformative or weak sparse prior (e.g., Beta(0.5,0.5)),
we fnd that similar prediction error rates were obtained for NaNOS as in 4.6.c. The
above analysis indicates that NaNOS is robust to the prior choice.
In addition to using the even splitting strategy with the same number of training
and test samples, we also tested the performance of all the algorithms in another
setting with more training samples – specifcally, 62 training and 16 test samples. We
repeated the random partitioning 50 times. The average error rates for NaNOS, elastic
net, lasso and group lasso are 8.00 ± 0.89, 9.90 ± 1.00, 12.0 ± 1.0 and 11.0 ± 0.14,
respectively. Again, the two-sample t test indicates that NaNOS outperforms the
alternative methods signifcantly (p < 0.05).
Three out of the fve pathways with the selection posterior probabilities larger
than 0.95 are discussed below. They were selected 35, 50 and 50 times in the 50
splits.
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The frst selected pathway was the TGF-β signaling pathway. It is essential in
epithelial-mesenchymal transition (EMT) – a critical component for developmental
and cancer processes – and related to PDAC (Krantz et al., 2012). The selected part
of this pathway is visualized in Figure 4.7.c. It shows that IFNG, TNF-α, LTBP1,
DCN, TGF-β, and its receptor TGF-β R1 were selected. The TGF-β ligand – via
its receptor – propagates the signal through phosphorylation of Smads including the
selected Smad 4, which in turn translocate into the nucleus and interact with Snail
TFs to regulate EMT (Krantz et al., 2012). The selected BMP ligand (i.e., BMP2) is
bound to BMP R1 and R2 receptors to activate Smad1, which is in a protein complex
including Smad4. (Gordon et al., 2009) showed that in PANC-1 cell line this protein
complex mediates EMT partially by increasing the activity of MMP-2.
The second identifed pathway was extracellular matrix (ECM)-receptor interaction. It is associated with desmoplastic reaction, a hallmark in PDAC (Shields
et al., 2012). In this pathway, NaNOS selected the integrin receptors – including
ITGB1, ITGA2, ITGA3, ITGA5, ITGA6 – and the ECM proteins – collagens inlcuding COL1A1 and COL1A2 and laminins including LAMC2 and LAMB3. Important
interactions among them were revealed in a previous study by Weinel et al. (1992).
The third chosen pathway was CAMs. CAMs are pivotal in pancreatic cancer invasion by mediating cell-cell signal transduction and cell-matrix communication (Keleg
et al., 2003). In this pathway, the selected molecules include calcium-dependent cadherin family molecules (CDH2, CDH3) and neural-related molecules (MAG); both of
them have shown to be related to PDAC (Kameda et al., 1999) (Keleg et al., 2003).

4.6

Discussion
As shown in the previous section, the new Bayesian approach, NaNOS, outper-

formed the alternative sparse learning methods on both simulation and real data by
a large margin. Now we discuss three factors that may contribute to the improved
performance of NaNOS.
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First, the spike and slab prior (4.3) and its generalization (4.4) in NaNOS separate
weight regularization from the selection of variables (pathways or genes). Both the
(generalized) spike and slab prior and elastic net can be viewed as mixture models,
in which one component encourages the selection of variables and the other helps
remove irrelevant ones. However, unlike the elastic net where the weights over l1 and
l2 penalty functions are fxed, the spike and slab prior has the selection indicators over
these two components estimated from data. When a variable is selected, the model
has a Gaussian prior over its value (i.e., weight) that is equivalent to a l2 regularizer
(as in ridge regression) and does not shrink the value of the selected variable as l1
penalty would do. By contrast, lasso or elastic net, with a fxed mixture weight, has
sparsity penalty over both pruned and selected variables, which can greatly shrink
the values of selected variables and hurt predictive performance.
Second, NaNOS incorporates correlation structures encoded in pathways for variable selection. Specifcally, it uses pathway structures into the extended spike and
slab prior to explicitly model the detailed relationships between correlated genes. In
contrast, Lasso and elastic net do not use this valuable correlation information in their
models. By comparing prediction accuracies of NaNOS when 0% and 100% edges are
removed from pathways (See Figure 4.8), we can see that the detailed correlation
information captured by the pathway topology can greatly improve modeling quality.
Third, NaNOS has the capability of selecting both relevant pathways and genes
due to its two-layer sparse structure. By contrast, with l1 /l2 penalty, group lasso
encourages the selection of all the genes in chosen pathways, leading to dense estimation. This may be undesirable in practice and deteriorate the predictive performance
of group lasso. NaNOS enhances the fexibility of group lasso by conducting sparse
estimation at both the pathway (or group) and gene levels. Meanwhile, our Bayesian
estimation e˙ectively avoids overftting, a problem often plaguing fexible models.
NaNOS has been applied to joint pathway and gene selection in this paper. Inspired by the seminal works in (Frohlich et al., 2006; Chuang et al., 2007; Srivastava et al., 2008; Zycinski et al., 2013), we can use NaNOS in a variety of biomedi-
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cal applications where there are abundant high-dimensional biomarkers of individual
samples and other information sources – for example, the gene ontology (GO) and
protein-protein interaction networks information – that capture correlation in the
high-dimensional space. Here we discuss two approaches to apply NaNOS when we
have only GO or other group information without network topology. The frst approach is to compute some distance or similarity scores between genes based on the
GO information (e.g., following the approach by Srivastava et al. (2008)) and then
estimate the network topology based on a network learning method, for example,
graphical lasso (Friedman et al., 2008). With the estimated network topology, we
can compute the graph Laplacian matrices and apply NaNOS to select genes and
groups of genes. The second approach is to directly use the group membership information in NaNOS by replacing the graph Laplacian matrices with identity matrices.
This approach becomes useful when we even do not have any information available
to learn the network topology. As shown in Figure 8, even when all the edges were
removed and we had only group information, NaNOS still outperformed the second
best method, elastic net, in terms of prediction accuracy.
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5. SUMMARY
5.1

Discussions
The ultimate goal of RNA-seq data analysis is to interpret biological mechanisms

based on the massive information stored in RNA-seq reads. Despite many successful applications of RNA-seq, how to extract solid and consistent information from
millions of pieced-together reads, and meanwhile to reduce the noise level is still a
critical challenge in RNA-seq data analysis. One of the most eÿcient strategies is
to utilize the additional information to facilitate this process. In this dissertation,
I have presented three studies in RNA-seq data analysis by incorporating disparate
information. The frst study takes the advantage of long read information in PacBio
sequencing for assessing the performance of de novo assembly by RNA-seq short reads.
The second study relies on the common information shared in sample replicates for
accurately quantifying the expression levels of transcripts, while keeping the sample
variations in estimation. The last study utilizes the pathway structural information
summarized by domain experts for selecting phenotype-associated genes and pathways from high-throughput genomic data. All the above studies demonstrate that,
by incorporating disparate information, the performance of RNA-seq data analysis
can be better assessed or improved in the steps from assembly to quantifcation, and
to functional analysis.

5.2

Perspectives
Aside from RNA sequencing, which quantifes and identifes the transcriptome of a

sample, many new sequencing techniques have been developed for measuring di˙erent
omics of a sample. For instance, exome sequencing only quantifes the protein-coding
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genes in a genome rather than quantifes the whole transcriptome as RNA-seq does;
ChIP-seq combines the chromatin immunoprecipitation with DNA sequencing for
identifying targeted protein binding sites on DNA; Assay for Transposase-Accessible
Chromatin using sequencing (ATAC-seq) identifes DNA regions which are accessible
to transposase, namely the regions having no proteins binding with; DNA-methylation
sequencing measures the epigenomic status of a sample.
One interesting direction is to combine multiple omics data to enhance the prediction performance, and to better illustrate the mechanism of gene regulation. Even
though each of the above sequencing techniques has focused on measuring di˙erent
aspects of a sample, they should provide consistent information for mutually supporting each other when the signal is true. For example, if we fnd high levels of
methylations in the promoter regions of a certain genes, the transcriptional rates of
these genes should be low in RNA-seq data.
From the perspective of computer science, machine learning and deep learning
algorithms can be applied to the multi-omics data. By reorganizing the multi-omics
data into meaningful and eÿcient data structures, and by appropriately choosing the
variables, both supervised learning and unsupervised learning algorithms, which have
been successfully used in many other areas, such as image processing, natural language processing, etc., can be applied to sequence data, for illustrating new biological
mechanisms. However, as the data has boomed, the curse of dimensionality has become increasingly severe. How to properly reduce the dimensionality by capturing
the correlative information remains as a critical question.
The other interesting direction is to investigate the “individual –population” relations of genomes or transcriptomes. Here, the “individual” can refer to a human
or a single cell. The 1000 genomes project sequenced the genomes of 1092 people
from di˙erent races/populations from all over the world. Single cell RNA-seq has the
ability to sequence the small amount of RNAs from each single cell. By clustering
the samples using each individual omics information, the history of human evolution
and the mechanism of disease progression can be revealed.
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Again, during only four decades, the feld of DNA sequencing has become more
prosperous than ever, by quickly absorbing knowledge from diverse areas, including
but not limited to chemistry, materials science, computer science, and engineering.
In the near future, the sequencing technology can be envisioned to enter the real life
of each person and better serve the world.
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